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General experimental methods 
 
1. NMR Spectras 
1H and 13C NMR spectra were recorded in CDCl3 solutions (where not otherwise stated) at room 
temperature on a Bruker AMX-300 spectrometer operating at 300 MHz for 1H and 75 MHz for 13C. 
Chemical shifts are reported as d values in parts per million (ppm), and are indirectly referenced to 
tetramethylsilane (TMS) via the solvent signal (7.26 for 1H, 77.0 for 13C) in CDCl3. Coupling 
constant (J) are given in Hz. 
2. Solvents 
Solvents were routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and ether (Et2O) 
were obtained by distillation from sodium-benzophenone ketyl; dry methylene chloride (CH2Cl2) 
and toluene were obtained by distillation from CaCl2. All reactions requiring anhydrous conditions 
were performed under a positive nitrogen flow, and glassware was oven-dried. 
3. Flash chromatography 
Isolation and purification of the compounds were performed by flash column chromatography on 
silica gel 60 (230-400 mesh); when necessary deactivated silica gel was used. 
4. Analytical thin-layer chromatography 
Analytical thin-layer chromatography (TLC) was conducted on Fluka TLC plates (silica gel 60 
F254, aluminium foil), and spots were visualized by UV light and/or by means of dyeing reagents. 
5. Melting points 
Melting points were determined on a Stuart Scientific SMP3 instrument and are uncorrected. 
6. HPLC analysis 
HPLC analyses were recorded on a Varian Prostar liquid chromatography Column description – 
Column size 250 x 4.6 mm (Lx I.D) Chiral Daicel OD lot no. 555-024-50303. 
7. Reverse phase chromatography 
Reverse phase silica RP-18 was used for isolation and purification of the compounds. 
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CHAPTER 1 
General Introduction 
1. Background 
 The birth of civilization can be traced back to the time when humans first began to cultivate 
crops – the so-called Neolithic revolution. This caused a dramatic increase in the number of people 
that could be supported in a given environment, but it also brought problems that farmers have had 
to contend with ever since. The devastation to crops mainly formed by weeds and pests (fungi, 
bacteria etc). Farmers all over the world, however, are on the frontline of the fight against these 
forces of destruction and some of their most important weapons are agrochemicals, which help to 
protect against the worst crop losses. In the absence of the remarkable levels of growth in the yields 
of important crops, neither the rapid increase in living standards in industrialized countries nor the 
adequate standard of nutrition for the greater part of the world’s population would have been 
possible. Alongside high-yielding varieties, improved agricultural techniques, and rapid 
mechanization, the chemical industry has also contributed substantially to progress in agriculture 
since roughly the middle of the nineteenth century. From the chemists ‘Kitchens’ came two ‘magic 
weapons’: artificial fertilisers and chemical agents for crops protection. Today both have become 
indispensable to modern yield and quality orientated agriculture. The word ‘agrochemicals’ has 
often assumed a pejorative (expressing disapproval) character in the public mind. 
 Feeding the world is an increasing challenge, on the other hand the size of arable land is 
limited and cannot be expanded without further inroads into vital natural habitats like the rain 
forests. As more people need more food per head from less land, the yields need to be increased by 
a combination of methods which is known as ‘Integrated Crop Management’. Chemical crop 
protection products with activity against weeds, plant diseases, insects and mites help the farmer to 
assure or increase yields. 
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 In modern days, we have become habitual to a wide variety of cheap, nutritious food which 
is one the basic needs of living organisms, while plants are the major source of food. Rapidly 
growing world population put tremendous pressure to increase and preserve the food supply, 
Additionally, in recent years public pressure to reduce the use of synthetic fungicides in agriculture 
has increased. Concerns have been raised about both the environmental impact and the potential 
health risk related to the use of these pesticides. 
 Throughout history, various types of pests, such as insects, fungi, weeds, bacteria, rodents 
and other biological organisms, have bothered humans or threatened human health. A large number 
of volumes and reviews have been written about the use of naturally products as pesticides,1-9 each 
having strengths and weakness when considering the vast array of compounds that have found use 
or are currently being used in crop protection. The chemical protection of crops probably began in 
pre-Roman times with the application of elemental sulphur (the Greek author Homer mention ‘pest-
averting sulphur’ see Williams and Cooper 10). Progress for the next few hundred years was 
unspectacular, burning bitumen, cow dung, tobacco, and mercury being some typical examples of 
protection methods. For controlling pests the era of synthetic pesticides really got going in the 
1950s with the carbamate insecticides, and 2,4-dichlorophenoxyacetic acid (2,4 D). These 
pesticides can be defined as a substance or mixture of substance used to kill a pest. A pesticide may 
be a chemical substance, biological agent (such as a virus or bacterium), antimicrobial, disinfectant 
or device used against any pest. 
 Fungicides are one of the classes of pesticides. Fungicides are chemical compounds, 
biological organisms to kill or inhibit fungi or fungal spores. Fungi are capable of causing serious 
damage in agriculture, resulting in critical losses of yield, quality and profit. Fungi are the number 
one cause of crop loss worldwide and cause about 70% of all major crop diseases. Although similar, 
Oomycetes are not fungi. However, they use the same mechanisms to infect plants (some of 
important diseases of crop plant are mentioned in table 1.1 with their common name and scientific 
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name). Consequently, in the study of plant disease (phytopathology), chemicals used to control 
oomycetes are also referred to as fungicides. As well as in agriculture, fungicides are used to fight 
fungal infections in animal tissues. Fungicides can be either contact or systemic. A contact 
fungicide kills fungi when sprayed on its surface; a systemic fungicide has to be absorbed by the 
plant. Although there are benefits to the use of fungicides, there are also drawbacks, such as 
potential toxicity to humans and other animals. Regarding these drawbacks, the agrochemical 
industry deserve for safer and more effective agrochemicals with reduced environmental and/or 
mammalian toxicity. Essential to these efforts is identification of new lead candidates possessing 
high levels of desirable biological activities, reduced unwanted toxicities, new structural types, and 
perhaps different modes of action, thereby providing protection from cross-resistance to currently 
used agrochemicals. 
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Table 1.1 Important Diseases of Crop Plants  
Pathogan  
Fungal Class Scientific Name Common Name 
Phycomycetes 
subclass oomycetes 
Phytophthora infestans 
Plasmopara viticola 
Pseudoperonospora 
Cubensis 
potato late blight 
downy mildew of grape 
cucumber downy mildew 
 
 Ascomycetes Pythium spp. 
Erysiphe graminis 
Gaeumannomyces graminis 
Podosphaera leucotricha 
Pyrenophora teres 
Pyricularia oryzae 
Rhynchosporium secalis 
 
Sclerotinia Spp. 
 
Sphaerotheca fuliginea 
Uncinula necator 
Venturia inaequalis 
Mycosphaerella fijiensis 
 
damping off diseases 
powdery mildew of wheat/barley 
take-all of oats and wheat 
apple powdery mildew 
net blotch of barley 
rice blast 
leaf scald of barley, brown rot of 
pome fruit 
Leaf Spot of brassicas and 
legumes 
cucurbit powdery mildew 
grape powdery mildew 
scab of apple 
sigatoka disease of bananas 
Basidiomycetes Puccinia Spp. 
 
 
Rhizoctonia Spp. 
 
Tilletia Spp. 
Uromyces Spp. 
Ustilago Spp. 
 
Leaf  rust of wheat and oats 
black scurf of potato 
Sheath blight of rice sharp eyespot 
of wheat 
Bunts of wheat 
Beans rust 
Smuts of wheat, barley, oat and 
maize, early blight of potato 
Deuteromycetes Alternaria Spp. 
 
Botrytis.Spp 
Cercospora Spp. 
 
 
Fusarium Spp. 
 
 
Helminthosporium Spp. 
 
Pseudocercosporella 
herpotrichoides 
Septoria nodorum, Septoria tritici 
early blight  tobacco brown spot 
leaf of brassicas 
grey mold of grape and other crops 
leaf spot of sugarbeet, brown  
eyespot of coffee 
wilts, broad range of hosts  blight 
of wheat 
root and foot rot of wheat leaf spor 
of maize 
eye spot of wheat 
 
glume blotch of wheat 
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1.1 Why are Fungicides Needed. 
 Diseases are a common occurrence on plants, often having a significant economics impact 
on yield and quality, thus managing disease is an essential component of production for most crops. 
Broadly, there are main reasons why fungicides are used. 
(a) To control a disease during the establishment and development of crop. 
(b) To increase the productivity of a crop and to reduce blemishes. Diseased food crops may 
produce less because their leaves, which are needed for photosynthesis, are affected by the disease 
(Fig.1.) Blemishes can affect the edible part of crop or, in the case of ornamentals, their 
attractiveness, that can affect the market value of the crop. 
(c) To improve the storage life and quality of harvested plants and produce. Some of the great 
disease losses occur post-harvest. Fungi often spoil sorted fruits, vegetables, tubers, and seeds. A 
few which infect grains produce toxins (mycotoxins) capable of causing severe illness or even death 
in humans and animals when consumed. Fungicides developed so far have not been sufficiently 
effective to be useful for managing mycotoxins associated with other disease. 
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Fig. 1 
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1.2 A Short History of Fungicides 
Farmers have been at the mercy of plant diseases since plants were first domesticated. The 
mysterious appearance of blights and mildews, apparently coming form nowhere, led to the theories 
of gods, vapors, demons, an decay as causes of disease. Beginning in the early 1800s, plant 
scientists and chemists began the long journey to discover and invent fungicides that would reduce 
disease losses. Many discoveries were made and summarized the exceptional few that irrevocably 
changed agriculture. (summarized in Table 1.2). 
1.2.1. 1807-The first fungicide 
B.Prevost discovered the first chemical means for controlling disease in a practical way in 1807. 
Bunts and smuts of cereals had been a key limitation to cereal cultivation for centuries, appearing 
unexpectedly on healthy-looking plants that should have been producing grain. Prevost was the first 
to observe that spores, which grew into tiny germinating “plants,” caused wheat bunt. He then made 
the serendipitous observation that a weak copper solution (generated when he held the spore 
suspension in a copper vessel) prevented their growth. Through experimentation, he demonstrated 
that farmers could control bunt by wetting wheat kernels with a copper sulphate solution. Previous 
methods of bunt control required steeping the seeds in salt water and lime of putrefied urine, which 
were not very effective.11 Copper-based seed treatments remained popular in some countries, 
including France, through the end of the 20th century. 
1.2.2. 1885- The First Foliar Fungicide. 
 Eight decades passed before a method of controlling foliar disease was discovered in 1885. 
P. M. A. Millardet described the effective use of a mixture of copper sulphate and lime for 
controlling the downy mildew on grapevines. A farmer in the Bordeaux region of France had mixed 
the unattractive concoction to discourage university students from pilfering grapes on their way to 
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class, and Millardet noticed that the sprayed vines retained their leaves while unsprayed plants had 
been defoliated by downy mildew.12 This unexpected discovery, thereafter known as Bordeaux 
mixture, stimulated research into other possible methods of controlling fungal diseases, a search 
that gained momentum during the 20th century. To this day, copper-based foliar fungicides are used 
to control a variety of fungal disease, particularly on fruits and vegetables, and for suppression of 
bacterial diseases. Many have new-found utility as disease control agents in organic food 
production. 
1.2.3. 1915-Broad-Spectrum Control of Seed-Borne Disease. 
 The first organic (carbon-based) fungicides synthesized in a laboratory were the 
organomercurial seed treatments. Even though copper seed treatments had been used on cereals for 
100 years, they controlled only bunt and could be phytotoxic. Early in the 20th century, discoveries 
made by fledging pharmaceutical companies studying the medicinal aspects of compounds made 
from metals and dyestuff intermediates stimulated plant pathologists to look for compounds that 
could control plant disease. The organomercurial seed treatment, chloro(2-hydroxyphenyl)mercury 
was introduced in Germany in 1913.13  Research on organomercurials continued through the 1920s 
and 1930s, leading to commercialization of the 2-methoxyethyl silicate and acetate salt of 2-
hydroxyphenyl mercury, among others. These seed treatments were a breakthrough for cereal 
farmers because the treatments had good seed safety and controlled mycelia of seed-borne fungi 
such as Fusarium and Dreschlera as well as bunt. They also provided protection against soil-borne 
Fusarium species, resulting in improved stand establishment14 and their vapor activity helped 
overcome incomplete coverage of the seed surface.15 
 The organomercurial seed treatments had some flaws. They were not deeply systemic, so 
loose smuts were not controlled. Despite their multi-site-mode of action and use only once per year, 
resistance eventually developed in some populations of Dreschlera on barley and oats. 
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Environmental toxicity and the persistence of mercury led most countries to ban the 
organomercurials when safer alternative became available. Despite the availability of alternative 
treatments, organomercurial seed treatments were not banned in the UK until 1992.14 
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           Table 1.2. Milestone fungicides. 
Common 
name 
Trade name 
(example)x  
Class of 
chemistry 
Year 
of 
launch 
Mode of 
action 
WHO 
toxicity 
classy  
Copper 
sulfate 
  Inorganic 1873 General 
toxicant 
II 
Chloro (2-
hydroxy 
phenyl) 
mercury  
UPSULAM Organo- 
mercurial 
1913 General 
toxicant 
        
Thiram   Dithio- 
carbamate 
1940 General 
toxicant 
III 
Ferbam   Dithio- 
carbamate 
1943 General 
toxicant 
U 
Mancozeb DITHANE™ Dithio- 
carbamate 
1961 General 
toxicant 
U 
Carboxin VITAVAX Carboxamide 1969 Mitochondrial 
electron 
transport 
Complex II 
U 
Benomyl BENLATE Benzimidazole 1970 β-tubulin 
synthesis 
U 
Triadimefon BAYLETON Triazole 1976 Ergosterol 
biosynthesis 
III 
Metalaxyl RIDOMIL, 
APRON 
Phenylamide 1977 RNA 
transferase 
III 
Fosetyl-
Aluminum 
ALIETTE Phosphonate 1977 Not 
conclusively 
determined 
U 
Azoxystrobin QUADRIS, 
AMISTAR, 
HERITAGE 
Strobilurin 1996 Mitochondrial 
electron 
transport 
Complex III 
U 
Tricyclazole BEAM™  Benzothiazole 1976 Melanin 
biosynthesis 
inhibitor 
II 
Probenazole ORYZEMATE Benzisothiazole 1979 Systemic 
acquired 
resistance 
U 
Acibenzolar-
S-methyl 
BION, 
ACTIGARD 
Benzo- 
thiadiazole 
1996 Systemic 
acquired 
resistance 
III  
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Quinoxyfen FORTRESS™  
QUINTEC™ 
Quinoline 1997 Signal 
transduction 
U 
 
x
 DITHANE™, BEAM™, FORTRESS™, and QUINTEC™ are trademarks of Dow AgroSciences LLC. 
 
y
 World Heath Organization classification for estimating acute toxicity of pesticides (25): II = Moderately hazardous; 
III = Slightly hazardous; and U = Product unlikely to present acute hazard in normal use. 
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1.2.4. 1969-The First Systemic Seed Treatment. 
The first systemic fungicide was a milestone both because it had true redistribution in the plant and 
because it had the potential to replace organomercurial cereal seed treatments. Carboxin, described 
in 1966 and commercialized in 1969, not only controlled surface-borne bunts and smuts but also 
penetrated deeply in the seed embryo, where it eradicated loose smut infection. Carboxin also gave 
excellent control of early season rust and Rhizoctonia damping off, although it was less effective on 
seed-borne Fusarium and Dreschlera disease than organomercurials.16 Additionally, carboxin had 
good plant safety as a seed treatment of row crops, particularly cotton and canola. Resistance 
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development has been slow, although field resistance was eventually documented in some 
populations of Ustilago nuda after many years of continuous use.17 Despite their excellent fit in 
limited markets, the utility of carboxin and its derivative of foliar application, oxycarboxin, was 
never broad because of their specificity for Basidiomycetous diseases. 
 
1.2.5. 1970- The First Broad-Spectrum Foliar Systemic Fungicide. 
The first fungicide with the broader spectrum typical of dithiocarbamates and the systemic activity 
of organophosphate insecticides was benomyl. This benzimidazole fungicide was launched by 
DuPont in 1970 and provided systemic and curative activity at low rates, with excellent plant and 
mammalian safety. For the first time, farmers were able to cure existing infections, extend intervals 
between sprays, and not worry about perfect coverage. These characteristics made benomyl 
extremely popular from its introduction.18 The list of fungi controlled by benomyl and other 
benzimidazole fungicides is extensive. Most Ascomycetes with light-colored spores are controlled, 
including numerous types of leaf spots, fruit rots caused by Botrytis and Penicillium, powdery 
mildews, and stem diseases such as eyespot. Some Basidiomycetes, such as selected anastamosis 
groups of Rhizoctonia solani, are controlled, but most are not. Diseases caused by Oomycetes and 
by Ascomycetes with dark spores (such as Alternaria and Helminthosporium) are also not 
controlled.19 Additional benzimidazole fungicides launched after the introduction of benomyl 
include thiophanate-methyl (1971) and carbendazim (1974). 
The characteristics that made benomyl so popular and effective also had a troubling aspect. 
Repeated, exclusive use on polycyclic diseases led to rapid development of resistant fungal 
populations. Within three years of introduction, resistance was reported in field and/or greenhouse 
populations of Erysiphe, Botrytis, Penicillium, and Cercospora.18 Benomyl’s single-site mode-of-
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action could be bypassed by the fungus with a single mutation. Resistant strains could be equal in 
fitness to their susceptible counterparts, resulting in persistence of some resistant populations even 
when the benzimidazole fungicides were discontinued.20 The agrochemical industry learned an 
important lesson about fungicides with specific modes-of-action from the benzimidazole 
experience, and now begins assessment of resistance risk early in fungicide development so that 
resistance management plans are in place at product launch.20 
The benzimidazole fungicides were very successful on fruits and vegetables but had less 
utility for cereal diseases, since they gave no control of rusts or Dreschlera species. Further, the 
cereal diseases that were controlled, in particular the powdery mildews, rapidly became resistant.18 
A systemic, broad-spectrum fungicide with a new mode-of-action was still needed for foliar disease 
control in cereals.  
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1.2.6. 1976-A Systemic, Curative Foliar Fungicide for Cereals. 
The breakthrough for cereal disease management came in 1976 with the introduction of the triazole 
fungicide triadimefon by Bayer.21 Triadimefon provided curative as well as protectant activity, low 
application rates, and excellent redistribution in the plant. The spectrum of control covered all major 
cereal diseases and included most Ascomycetes and Basidiomycetes (but not Oomycetes). 
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Additional triazole fungicides were introduced over the next two decades with improved potency 
and plant safety on cereals (e.g., epoxiconazole), a broader effective spectrum (e.g., propiconazole, 
tebuconazole), or specialized applications (e.g., difenoconazole and triticonazole for seed 
treatment)21. The triazole fungicides significantly increased farmers’ expectations for fungicides, 
particularly for reach-back (curative) activity and redistribution to unsprayed growth. 
The revolutionary triazoles have not been immune to challenges in their development and 
maintenance. They have well-documented side effects on plants. Application to shoots and roots 
often reduces elongation and causes leaves to be smaller, thicker, and greener. Treated plants may 
be delayed in senescence, which can impede harvest or improve yields, depending on the crop.22 A 
larger concern has been resistance development, since the triazoles have many of the same 
properties as the benzimidazoles (curative activity, single-site MOA, multiple applications per 
season). Resistance to the triazole fungicides (and other inhibitors of C14-demethylase in ergosterol 
biosynthesis) developed first in the powdery mildews and has been observed (but is less 
problematic) on other diseases.21 Unlike resistance to the benzimidazoles, resistance to the triazoles 
involves multiple genes with intermediate levels of resistance and incomplete cross-resistance 
between different fungicides.22 The use of mixtures has been remarkably successful in maintaining 
useful activity against most fungal targets for three decades. 
The launches of benzimidazole and triazole fungicides provided potent, systemic fungicide 
solutions for Ascomycete and Basidiomycete diseases, but control of devastating Oomycete 
diseases such as potato late blight and grape downy mildew was limited to frequent sprays of 
protectant fungicides. Root rots of established plants (caused by Phytophthora and Pythium) and 
systemic downy mildews could not be controlled at all, and took an unknown toll on crop yield.  
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1.2.7. 1977-The First Systemic Oomycete Fungicides 
The launch of the phenylamide fungicide metalaxyl in 1977 by Ciba-Geigy changed farmers’ 
expectations for control of Oomycete diseases.23 This fungicide was an immediate success because 
of its outstanding properties: high potency; excellent curative and protectant activity; excellent 
redistribution and protection of new growth; control of all members of the order Peronosporales 
(including Pythium); and flexible application methods including foliar spray, seed treatment, and 
root drench.24 As with the benzimidazoles, the phenomenal success and overuse of the phenylamide 
fungicides led to rapid resistance development. Significant resistance to metalaxyl was first 
described in 1980 on cucumber downy mildew and late blight.23 Resistance developed more rapidly 
where metalaxyl was used alone, disease pressure was very high, and applications were made 
curatively. Ciba-Geigy responded with the development of fungicide prepacks containing metalaxyl 
and protectant fungicides, such as mancozeb, which extended the product life significantly.23,24 The 
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phenylamide experience was pivotal in the formation of the Fungicide Resistance Action 
Committee (FRAC), which developed a coordinated strategy across rival companies to limit the 
number of recommended phenylamide applications per season.25 Despite a coordinated effort, 
susceptibility to phenylamides gradually eroded in populations of many foliar pathogens, and foliar 
uses of metalaxyl are now met by other fungicides in many markets. Soil and seed applications of 
metalaxyl (or its active enantiomer, mefenoxam) have generally retained their effectiveness, 
particularly for control of Pythium and the root-infecting species of Phytophthora. 
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1.2.8. 1996-Broad-Spectrum Fungicides with Novel Spectrum and New Mode-of-
Action 
The natural products strobilurin A and oudemansin had been isolated from a saprophytic fungus in 
the late 1970s and demonstrated excellent broad-spectrum control of fungal growth. Parallel 
research programs at ICI and BASF in the early 1980s were focused on invention of synthetic 
analogues with improved UV stability and spectrum.25 These strobilurins differed from previous 
fungicides in combining an unusually broad spectrum (including control of Oomycetes, 
Ascomycetes, and Basidiomycetes) with a site-specific mode-of-action. The first strobilurin 
products were launched in 1996; kresoxim-methyl from BASF had strong utility on cereals, and 
azoxystrobin from Zeneca was suitable for a variety of crops due to its plant safety and strong 
redistribution. Additional strobilurins, including trifloxystrobin, picoxystrobin, and pyraclostrobin, 
have been launched by a number of companies. These compounds became popular in many markets 
because of their versatility at controlling diseases from different taxonomic classes, such as 
powdery and downy mildew on vines, and sheath blight and blast on rice.26 An additional benefit 
came from the physiological response of the plant to the fungicide; as with the triazoles, strobilurins 
often enhanced plant greening and delayed senescence, leading to improved yields even in the 
absence of significant disease pressure.26,27 Some of the strobilurin fungicides commercialized after 
azoxystrobin were tailored to the cereal market rather than the vegetable and fruit market, with 
attributes of long residual protection, vapor phase activity, and moderate redistribution. Widespread 
use of strobilurins has already led to the development of resistance for several diseases, including 
wheat, barley, and cucumber powdery mildew, grape and cucumber downy mildew, apple scab, 
black sigatoka on bananas,27 and Septoria blotch on wheat.28 Resistance is typically caused by 
single base pair mutations in the mitochondrial gene encoding cytochrome b.27 Current 
recommendations for use of strobilurin fungicides limit the number of applications per season, 
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suggest alternation of application with fungicides that have different modes-of-action, and 
recommend mixtures for many markets.27 
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1.2.9. 1976-1996-Fungicides with indirect Modes-of-Action 
Increasing environmental and regulatory pressures built interest in fungicides that act on the plant-
pathogen interaction rather than the fungus.29 These compounds are not toxic to the isolated fungus, 
and should be more environmentally benign. It is not even clear if they should be called fungicides 
since they do not kill fungi directly. The first  compound developed was tricyclazole, introduced in 
1976. This systemic fungicide (as well as the newer carpropamid) inhibits melanin biosynthesis, 
which is required for penetration of the leaf by the appressorium of some fungi.30 Utility is limited 
mainly to rice blast. Quinoxyfen, a compound from Dow AgroSciences that is highly specific for 
powdery mildews, also acts by inhibiting the fungus’ ability to initiate infection. Molecular studies 
suggest that quinoxyfen disrupts the infection process by inhibiting early fungus-plant signaling 
events and interfering with the fungus’ ability to make the morphological changes necessary for 
infection.31 
Other fungicides have been commercialized that act through stimulation of the plant’s 
natural defence response. Probenazole is a systemic compound that indirectly controls rice blast and 
some bacterial rice diseases. It stimulates the accumulation of toxins and enzymes associated with 
systemic acquired resistance in rice, but is ineffective in other cereals.14,32 Acibenzolar-S-methyl 
has the widest spectrum of activity among the non-fungitoxic compounds developed to date. It is 
active against various fungi, bacteria, and viruses and is highly mobile, with both acropetal and 
basipetal transport, but is rapidly metabolized.26 It stimulates the plant’s natural defense system, and 
must be applied as a protectant treatment several days before infection. It has been developed for 
use against powdery mildews in cereals, rice blast, sigatoka diseases of banana, and blue mold of 
tobacco.26  
A challenge for treatments that elicit resistance responses in plants is the potential reduction of 
yield. Alteration of the production of secondary metabolites in plants has a demonstrated fitness 
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cost in some cases, resulting in diminished plant growth.33 This yield drag in the absence of disease 
may limit the future development of compounds that alter plant metabolism, especially if the 
compound must be applied before disease pressure is significant.  
Because these compounds do not place selection pressure directly on fungal growth, they 
were expected to be more durable than conventional fungicides and unlikely to stimulate resistance 
development. Resistance has developed, however, for some compounds with indirect modes of 
action. Tricyclazole has remained effective for three decades, but resistance rapidly developed to 
carpropamid,30 despite both being inhibitors of melanin biosynthesis. Resistance to quinoxyfen 
developed in the wheat powdery mildew population in Europe after more than five years of 
intensive use.34 On the other hand, the compounds which act by stimulating host resistance have 
remained effective.  
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1.3 Application Methods 
Fungicides are applied as dust, granules, gas and most commonly, liquid. They are applied to  
1. Seed, bulbs, roots of transplants and other propagative organs. These treatments are usually 
done by the seed company. Some treatments need to be done by the grower on-site at the 
time of planting. The goal is to kill pathogens that are on the planting material or to protect 
the young plant from pathogens in the soil. 
2. Soil either in-furrow at planting. After planting as a soil drench (including through drip 
irrigation), or as a directed spray around the base of the plant. 
3. Foliage and other aboveground parts of plants by means of sprayer. 
4. Inside of trees via trunk injection. 
5. Air in enclosed areas such as greenhouse and covered soil. Fungicides are called fumigants 
when applied as a vapour-active chemical in the gaseous phase. Some fumigants are also 
active against nematodes, insects and weed seeds. 
6. Harvested produces, as a dip or spray in the packinghouse. 
Fungicides are used as a formulated products consisting of an active ingredient plus inert 
ingredients that improve the performance of the products. Fungicides are typically mixed with water 
then applied by spraying. Application equipments ranges from small hand held and back-pack 
sprayers to large spray units carried by tractors or aircraft. A few fungicides are applied as a dust. 
Fungicides can also be applied in greenhouse as smoke. Mist fog or aerosol. 
 A look at the history of fungicides gave us some idea of what to expect in the future. The 
major changes in fungicide use have usually been associated with changes in the spectra of 
pathogens as well as in crop intensities, practices of prices. 
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 In the above section historical perspective clearly reflects applications, advantages, and 
limitations of mostly each commercialized groups of fungicides. Clearly understanding of historical 
development of fungicides proves the major contribution of natural products in crop protection  
such as strobilurins. Our special orientation towards the natural products considers them in terms of 
safety of both, environment and human health. Additionally, successful story of strobilurins in crop 
protection motivated us to work in the area of natural products synthesis, which should contribute in 
the research of crop protection. At the end, we should try to meet the aspects and challenges of 
fungicide research. 
Nature is a rich source of compounds exhibiting biological activity against weeds, plans 
diseases, insects and mites. Natural products, with their tremendous structural diversity, are an 
important source of new toxophores. Many of these natural products have complex structures, 
insufficient biological activity and low persistence under field condition. Thus the share of natural 
products being used as active ingredients per se in today’s crop protection market is relatively 
small. In some cases the natural products have been further modified to provide semi-synthetics 
derivatives with improved biological properties. More importantly, natural products served as lead 
structures inspiring chemists to prepare new synthetic analogues with often improved biological 
activity, simplified structure, increased safety towards human and the environment an optimized 
persistence.  
1.4 What is a natural substance    
 A scientist and a lay-person perhaps have a different understanding of what the term 
‘natural’ conveys. Similarly, the motivation for investigating the use of natural products in plant 
protection might also be different. By definition, a natural or biogenic substance is either 
synthetized directly by a living organism or is derived form substance of biogenic origin by 
chemical reaction occurring without human intervention; for example by decomposition of 
biological materials. Thus, humus, or in the wider sense coal, oil and limestone, are examples of 
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natural or biogenic substance. A natural products is viewed as a physiologically active chemical 
which is synthetized by plants, animals or microbes. In contrast, a synthetic chemical is one which 
does not occur naturally and must be synthetized from other substance by human intervention. Of 
course, many naturally occurring substance can also be synthetized in the laboratory, and indeed the 
use of a pure, chemically synthetized molecule in laboratory tests in usually a pre-requisite for the 
acceptance of biological activity attributed to a particular substance in complex mixture form a 
natural source. 
1.5 Natural products in crop protection 
Natural products have been used for the benefit of humankind for many thousands of years, be it for 
food, clothing, cosmetics, construction of shelters and traps, tools and weapons, poisons for game 
and fish, medicines or crop protection agents. Where a physiological effect on a pest was required, 
early compounds were simply extracted from a source and used as an impure mixture of chemicals, 
one or more of which gave the required response. The science of natural products has advanced 
significantly in recent times, and these compounds are being used as products in their own right as 
pure (or at least characterised) compounds, as new chemical skeletons that can be modified by the 
ingenious synthesis chemist or as indicators of new, effective biochemical modes of action 
(increasingly important in a world of high-through put in vitro screening). A large number of 
volumes and reviews have been written about the use of natural products as pesticides. Most of 
these literature deals with compounds with promising activity that are not commercially available. 
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1.5.1 Kasugamycin 
 Kasugamycin and kasugamycin hydrochloride hydrate were isolated form the soli 
actinomycete Streptomyces kasuganesis Hamad et al. and were first described by Umezawa eta al. 
in 196535 and introduced by Hokko Chemical Industry Co. Ltd. The product is sold as a 
hydrochloride. The biological activity of these compounds was first described by Hamada et al.36 in 
1965. Kasugamycin is recommended for the control of rice blast (P. oryzae; perfect stage M. grisea) 
in the rice, leaf spot in sugar beet and celery (Cercospora spp.), bacterial disease in rice and 
vegetables and scab (Venturia spp.) in apples and pears. Kasugamycin is a systemic fungicide and 
bactericide with both protectant and curative properties. Resistance to kasugamycin was detected 
within 3 years of its introduction in 1965, and by 1972 it had become a serious problem in Japanese 
rice field. Today, mixture of kasugamycin with other fungicides with different mode of action are 
used. Kasugamycin inhibits hyphal growth of P.oryzae on rice, preventing lesion development; it is 
a comparatively weak inhibitor of spore germination, appressorium formation and penetration into 
the epidermal cells. In contrast, against Fulvia fulva (Cooeek) Cif. on tomatoes, inhibition of 
sporulation is high, but its effects on hyphal growth are poor. Kasugamycin is taken up by plan 
tissue and is translocated. 
 Kasugamycin hydrochloride hydrate is sold as WP, DP, soluble concentrates (SL) and 
granule (GR) formulations under the trade names Kasugamin, Kasumin and Kasu-rab-valida-sumi 
(plus phthalide plus validamycine plus fenitrothion) from Hokko. It is applied as a foliar spray, a 
dust or a seed treatment at rates from 20g AIL-1 . There has been evidence of slight phytotoxicity 
on crops such as peas, beans, soybeans, grapes, citrus and apples. No injury has been found on rice, 
tomatoes, sugar beet, potatoes and many other vegetables. The use of kasugamycin has declined 
following the rapid onset of resistance and the release of new, disease-specific chemical fungicides 
for rice blast control. As with other aminoglycoside antibiotics, Kasugamycin is not considered to 
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be toxic to mammals and there is no evidence that it has had any adverse effects on non-target 
organisms or on the environment. 
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1.5.2 Blasticidin S 
 Blasticidin S was isolated from the soil actinomycete, Streptomyces griseochromogenes 
Fukunaga in 1955 by Fukunaga et al,37 and later by Takeuchi et al,38 in 1958. Its fungicidal 
properties were first described by Misato et al.39 It is usually sold as benzylaminobenzenesulfonic 
acid salt. Blasticidin S is used to control the rice blast [Pyricularia oryzae Cavara; perfect stage 
Magnaporthe grisea (Hebert) Barr] by foliar application. Blasticidin-S inhibits protein biosynthesis 
by binding to the 50S ribosome in prokaryotes (at the same site as gougerotin), leading to the 
inhibition of peptidyl transfer and protein chain elongation. It is a contact fungicide with protective 
and curative action, exhibiting a wide range of inhibitory activity on the growth of bacterial and 
fungal cells. In addition, it has been shown to have antiviral and antitumour activity. It inhibits 
spore germination and mycelial growth of P. oryzae in the laboratory at rates below 1mgmL-1. It is 
sold as dustable powder (DP), emulsifiable concentrate (EC) and wettable powder (WP) 
formulations under the trade name Bla-S by Kaken, Kumiai and Nihon Noyaku. For control for rice 
blast it is used at rates between 1000 and 300 g Alha-1 by foliar application. Damage can be caused 
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to alfalfa, aubergines, clover, potatoes, soybean, tobacco and tomatoes. Excessive application 
produces yellow spot on rice leaves. In recent years, its significance as a fungicide has decreased 
following the introduction of new lower-toxicity, pathogen-specific, synthetic rice blast products. 
Blasticidin-S is relatively toxic to mammals, with the acute oral LD50 to rodents being below 100 
mgkg-1 . It is also a severe eye irritant. It is relatively non-hazardous to non-target organisms when 
used as labelled and has no deleterious effect on the environment. 
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1.5.3 Mildiomycin 
Mildiomycin was isolated from the soil actinomycete Streptoverticillium rimofaciens strain B-98 
891 and first reported by Harada and Kishi;40 its fungicidal properties were reported by Kusaka et 
al. in 1979.41 Mildiomycin used to control powdery mildews [Erysiphe spp, Uncinula necator 
(Schwein) Burrill, Podosphaera spp. And Sphaerotheca spp.] in ornamentals. The mode of action 
of mildiomycin is believed to be inhibition of protein biosynthesis in fungi by blocking peptidyl-
transferase.42 In the field, it is effective as an eradicant, with some systemic activity. Mildiomycin is 
specifically active against the pathogens that cause bacteria. 
 It is sold as a WP formulation under the trade name Mildiomycin by Sumitomo Chemical 
Takeda. Rates of use to eradicate infection and offer subsequent protection are from 50 to 100 mgL-
1.Mildiomycin has not been widely used for disease control outside Japan. Mildiomycin has very 
low mammalian toxicity and it has not been shown to have any adverse effects on non-target 
organisms or the environment. 
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1.5.4 Natamycin 
Natamycin (also known as myprozine, pimaricin and tennecin) is a secondary metabolite of the 
actinomycetes Streptomyces natalensis Struyk, Hoette, Drost, Waisvisz, Van Edk & Hoogerheide 
and S. Chattanoogensis Burns & Holtman. Its structure was established by Golding et al44 and 
Meyer,44 and its sterochemistry was revised by Lancelin and Beau,45 and Duplantier and 
Masamune.46 It was introduced as a fungicide by Gist-Brocades N V. Natamycin is used to contol 
various fungal disease, but especially basal rots on ornamental bulbs such as daffodils that are 
caused by Fusarium oxysporum. Schlecht. It is usually applied as a dip in combination with a hot 
water treatment prior to planting. Its precise mode of action is not known. Natamycin was sold as 
WP under the trade name Delvolan, but it is now withdrawn. Natamycin is not toxic to mammals or 
fish and is readily biodegradable.47,48 No adverse effects have been observed on non-target 
organisms or on the environment. 
 
Plant diseases are known from times preceding the earliest writings. Fossile evidence 
indicates that plants were affected by disease 250 million years ago. The Bible and other early 
writings mention diseases, such as rusts, mildews, blights, and blast that have caused famine and 
other drastic changes in the economy of nations. Some of the plant disease out breaking with similar 
far-reaching effects in more recent times include. 
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1.5.6 The polyoxins 
The fungicidal polyxins are polyoxin B and polyoxorim (BSI, pa ISO). Polyoxin B is one of the 
secondary metabolites produced by fermentation of the soil actinomcete Streptomyces cacoai var 
asoensis Isoono te al. It was first isolated by Isono et al,49 in 1965 and was introduced as a 
commercial fungicide by Hokko Chemial Industry Company Ltd, Kaken Pharmaceutical company 
Ltd, Kumiai Chemical Industry Company Ltd, and Nihon Nohyaku Company Ltd. Polyoxorim 
(polyoxin D) was isolated by Suzuki et al50 and Isono et al.51 The zinc salt was introduced as a 
fungicide by Kaken Pharmaceutical Company Ltd, Kumiai Chemical Industry Company Ltd and 
Nihon Nohyaku Company Ltd. Polyoxin B is used to contol a range of plant pathogenic fungi such 
as Sphaerotheca spp. and other powdery mildews, Botrytis cinerea Pers., Sclerotinia sclerotiorum 
De Bary, Corynespora melonis Lindau, Cochliobolus miyabeanus (Ito & Kuribay) Drechsler ex 
Dastur, Alernaria alternate (Fr.) Keissler and other Alternaria species in vines, apples, pears, 
vegetables and ornamentals. The primary use of polyoxorim is for the control of rice sheath blight, 
R solani. It is also effective against apple and pear canker [Nectria galligena Bresadola (Diplodia 
pseudodiplodia Fuckel)] and Drechslera spp., Bipolaris spp., Curvularia spp. and 
Helminthosporium spp. with the major use being in rice, although it also has application in pome 
fruit and turf. Polyoxins cause a marked abnormal swelling on the germ tuves of spores and hyphal 
tips of the pathogen, rendering the treated fungus non-pathogenic. In addition, the incorporation of 
[14C] gulcosamine into cell wall chitin of C. miyabeanus is inhibited. Polyoxins apparently exert 
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their effects through inhibition of cell wall biosynthesis.53,54 They are systemic fungicides with 
protective action. Polyoxin B is effective at controlling a variety of fungal pathogens, but is 
ineffective against pear black spot and apple cork spot (Alternaria Spp.), grey moulds (B. cinerea) 
an other sclerotia-forming plant pathogens. Resistance to polyoxin B has been found in A alternata 
in some orchards in Japan following intensive treatment. Polyoxin has good activity against rice 
sheath blight when applied as a foliar spray at rates of about 2 gL-1. It can be used to control apple 
and pear canker when applied as a paste. It is also ineffective against bacteria and yeasts.  
 The polyoxins are sold as WP, EC, water soluble granule (SG) and paste (PA) formulations. 
Polyoxin B is sold under a variety of trade names including Polyoxin AL by Kaken, Kumaiai, 
Nihon Nohyaku and Hokko and Polybelin by Kumiai. Polyoxorim trade names include Endorse, 
Polyoxin A and Stopit as symptoms appear.  
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1.5.7. Validamycin  
 
 Validamycin (also known as validamycin A) was isolated from the soil actinomycete 
Streptomyces hygroscopicus (Jensen) Waskman & Henrici isolate limoneus. Its biological activity 
was described by Horii et al.54 Validamycin is used for the control of R solani and other Rhizoctonia 
species in rice, potatoes, vegetables, strawberries, tobacco, ginger, cotton, rice, sugar beet and other 
crops. Validamycin is non-systemic, but has a fungistatic action, showing non fungicidal action 
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against R solani, but causing abnormal branching of the tips of pathogen followed by a cessation of 
further development.55 Validamycin has a potent inhibitory activity against trehalase in R solani 
AG-1, without any significant effects on other glycohydrolytic enzymes tested.56 Trehalose is well 
known as a storage carbohydrate in the pathogen, and trehalase is believed to play an essential role 
in the digestion of trehalose and transport of glucose to the hyphal tips. Very low rates of use give 
excellent control of R solani in various crops, and rates of 0.3g AIL-1 give effective control of rice 
sheath blight. It is applied as a foliar spray, a soil drench, a seed treatment or by soil incorporation. 
Validamycin is sold as DP, DL, powder seed treatment (DS) and liquid formulations under a wide 
variety of trade names including Validacin, Valimun, Dantotsupadanvalida (plus captan 
hydrochloride plus clothianidin) and Hustler (plus captan hydrochloride plus clothianidin plus 
ferimzone plus phthalide) by Sumitomo Chemical Takeda, Sheathmar by Sumitomo Chemical 
Takeda and Dhanuka, Mycin by Sanonda, Rhizocin by Nagarjuna Agrichem, Solacol by Bayer 
Crop Science, Valida by Nichimen, Kasu-rab-valida-sumi (plus fenitrothion plus kasugamycin plus 
phthalide) and kasurabvadlidtrebon [plus etofenprox plus kasugamycin hydrochloride hydrate plus 
phthalide)] by Hokko and Vivadamy and Vimix (plus 1-naphthylacetic acid plus 2-
naphththyloxyacetic acid) by Vipesco. Concentrations as high as 1 gL-1 showed no phytotoxicity to 
over 150 different target crops. Validamycin continues to find wide range of application in a wide 
variety of crops, particularly in Japan. Validamycin is not considered to be toxic to mammals and 
has no adverse effects on non-target organisms or on the environment. 
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1.5.8 Soraphen A 
Soraphen A was discovered by the research groups of Reichenbach and Hofle at GBF57, In their 
screening of extract form myxobacteria, a sample from Sorangium cellulosum stain So ce26 showed 
broad antifungal in vitro activity. The new metabolite soraphen A which was mainly responsible for 
the activity, was isolated and fully characterized by NMR and X-ray crystallography.57 The total 
synthesis of soraphen A was achieved by Giese and coworkers.58 Greenhouse tests at Ciba-Geigy 
soon revealed the high potential of soraphen as a plant protection agent against fungal pathogens. 
Field tests met the high hopes generated by the greenhouse results, and economical application rates 
seemed feasible. 
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1.5.9 Bilanafos 
The tripeptide bilanafos was originally isolated from the soil-inhibiting actinomycyete S. 
hygroscopicus, and was introduced as a herbicide produced by fermentation by Meiji Seika59,60, it is 
also produced by S. viridochromeogenes (Krainsky) Waksman & Henrict.61 
 Bilanafos is used post-emergence in vines, apples, brassicas, cucurbits, mulberries, azaleas, 
rubber and many other annual weeds in crop situations and for control of annual and perennial 
weeds on uncultivated land. Bilanafos itself is not directly phytotoxic but must be metabolically 
converted by the target plant to the actual phytotoxin, phosphinothricin {4-
[hydroxy(methyl)phosphinoyl]-L-homoalanine}, a potent irreversible inhibitor of glutamine 
synthesize.  
 Bilanafos is sold as SP and liquid formulations under the trade name Herbiace (introduced 
by Meiji Seika in 1988). It is applied post-emergence at rates of 0.9-1.8 kgAIha-1 for control of 
annual weeds and at higher rates for control of perennial weeds. When applied post weed 
emergence in crop situations, it must be directed at the weed and away from the crop. Bilanafos is 
relatively non-toxic to mammals and other non-target organisms.62,63 They have very little activity 
in soil, mainly owing to rapid microbial degradation. They are considered to be low environmental 
impact herbicides. 
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1.6 The Future of Fungicides 
Fungicides have changed the nature of agriculture. Each key invention was rapidly incorporated 
into farming practice and raised farmers’ expectations for the next breakthrough in performance. 
The success of these breakthroughs has been attenuated in some cases by development of resistance 
in the targeted fungi. Experiences with fungicide resistance have spurred improvements in fungicide 
stewardship. 
The report titled “Global Crop Protection Industry Outlook to 2016-Bio-pesticides: The 
Next Generation Crop Protection products” provides a comprehensive analysis on the size of 
agrochemical market, fungicides, herbicides, insecticides and bio-pesticides, micro-nutrients and 
adjuvant segments. The report covers the sales of crop protection products across all the regions in 
the world with detailed coverage on Europe, Asia and NAFTA region and 9 countries including the 
US, Canada, India, China, Japan, Germany, France, Italy and Spain. Talk among the watchers of 
worldwide crops indicates the global use of fungicides will continue to outpace. The global 
agrochemical market will keep growing in the future around 2% annually between 2010 and 2015, 
according to “Crop protection & Agriculture Biotechnology Consultant” head Phillips McDougall. 
However, fungicides are expected to have a higher growth rate than insecticides, so in the mid term 
(by 2015) fungicides will have a higher market value than insecticides. Fungicides are primarily a 
crop-driven market that drives yield. 
Significantly, high soft commodity process also plays a key role in fungicides usage. A 
primary indicator of the soft commodity market is cotton. For example, the US market saw historic 
levels of increases in 2010 with prices spiking 80% in summer months to the $1.30-a-pound range. 
“Due to high soft commodity prices, farmers have been willing to invest in their crops and apply 
fungicides even in situations with less disease pressure,” says Elise Kisling , BASF head of media 
relations, crop protection. 
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Five products currently drive the fungicide market. 
• Azoxystrobin ($1 billion annually)  
• Pyraoxystrobin ($700 million)  
• Mancozeb ($600 million)  
• Chlorothalonil ($535 million)  
• Copper-based fungicides ($450 million)  
A new trend emerging among fungicide manufacturers is treating “disease complexes” with 
chemicals that stem more than one disease state. These inhibitors “kill a whole trend of diseases.  
The main requirements for fungicides today are effective disease control, broad spectrum 
control, physiological effects, use restriction due to the regulatory profile, maximum residue levels, 
resistance management, and easy-to-use formulations. 
BASF is planning to address the needs of farmers with several new technologies. In 
fungicides, the main innovations will be Xemium, which has an active ingredient for broad-
spectrum disease control in a wide range of crops for reliable and flexible use, which provides 
higher yield and improved quality, and Initium, which has an environmentally friendly chemistry 
with a new mode of action for vine and vegetable growers. 
An increase in worldwide demand for high-quality food is perhaps the most compelling 
factor driving fungicide use. This is particularly true of driving the yield of Europe’s wheat and 
barley, fruits and vegetables, soybeans, rice, and maize. 
Feeding a growing world population is daunting to today’s farmers. “Today’s growers face a 
huge challenge: They will be instrumental in feeding a growing global population,” says Pete 
Thomas, global portfolio manager, DuPont Crop Protection. “We will need to double food 
production by 2050 if we are to meet this escalating need. Clearly, improving crop productivity and 
protecting food quality is part of that equation.” 
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People in rapidly developing countries including China and India are demanding higher 
volumes of food, and seeking more nutritious food. Those desires are increasing demand for many 
commodities, from grains to protein sources, which has in turn put upward pressure on commodity 
prices. 
As growers begin to see the benefits of fungicides in helping them achieve this goal, they are 
more willing to invest in the technology. The more willing they are to invest, the more valuable 
crop protection is to the marketplace. 
 Thus the major multinational companies will be focusing their future on an integration of 
genetic traits and agrochemicals. Projected growth of the agrochemical market is 3.4% over the next 
5 years, whereas traits are forecast to grow at 7%. The average current (2005) R & D expenditures 
of the six major Agro companies are 64.5% for chemistry and 35.5% for seed and traits. This 
endures that new fungicides will continue to be developed to protect the ever more precious 
cultivars, where they do not have sufficient genetic disease resistance. This balance between genetic 
resistances and disease control products of chemical, biochemical or biological nature will reamin 
and is not likely to change dramatically in the near future. Equally important for sustainable disease 
control will be the intelligent integration of these technologies with sound cultural and sanitation 
measures. 
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Chapter 2 
 
 
Scope of the thesis 
 
 
New fungicides, including natural product based fungicides, are being discovered and developed to 
replace the compounds lost due to the new registration requirements. A new product needs to be 
highly active against the target species and needs to have the desired biological spectrum which is 
defined by the farmer’s needs and the company’s product portfolio. It should not be cross-resistant 
to existing products and therefore new modes of action are desirable. Furthermore, it should not 
cause damage to the crop, in which it is used, and should be safe for the farmer, the consumer, and 
the environment. 
 Natural products have been used for the benefit of humankind for many thousands of year, 
be it for food, clothing, cosmetics, construction of shelters and traps, tools and weapons, poisons for 
game and fish, medicines or crop protection agents. Where a physiological effect on a pest was 
required, early compounds were simply extracted from a source and used as an impure mixture of 
chemicals, one or more of which gave the required response. The science of natural products has 
advanced significantly in recent times, and these compounds are being used as products in their own 
right as pure (or at least characterised) compounds, as new chemical skeletons that can be modified 
by chemists or as indicators of new, effective biochemical modes of action (increasingly important 
in a world of high-through put in vitro screening). An important benefit of natural product based 
fungicides is their relatively short environmental half-lives, which is due to the fact that they do not 
possess ‘unnatural’ ring structures and contain relatively few halogen substituents, offer advantages 
in that they can sometime be specific to a target species and often have unique modes of action with 
little mammalian toxicity. Moreover these compounds are perceived to be environmentally benign.  
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A large number of volumes and reviews have been written about the use of natural products 
as pesticides. Most of these literature deals with compounds with promising activity that are not 
commercially available. A survey of recent literature supplies lists of novel bioactive compounds, 
which have been reported very recently and show promising biological activity. Among a number 
of possible candidates we have selected three natural products, Farinomalein, Epicoccamide, and 
Harzianic acid as a synthetic targets. Thus, the aim of our thesis is to synthesize these natural 
products, their analogues in order to study the SAR and evaluation of their biological activity. 
In chapter 3, we discuss Farinomalein with respect to the isolation, structure elucidation, 
antifungal activity, study towards the synthesis and biological results. We also discuss previously 
reported synthesis of farinomalein and its drawbacks. We have overcome this drawbacks and report 
a different synthetic approach to farinomalein, developed in four steps with high yield and without 
using any hazardous chemical.   
 In chapter 4, we describe the efforts towards the first total synthesis of Epicoccamide D. 
Epicoccamid D is quite unusual since it is composed of three biosynthetically distinct subunits; 
glycosidic, fatty acid and tetramic acid. The epicoccamide D has significant antifungal and plant 
growth promotion effect, which makes it a potential lead for the design of new antifungal. Its 
biological activity and novel chemical structure has made this compound an attractive target for 
chemical synthesis.  
 In chapter 5, we describe the efforts towards the first total synthesis of Harzianic acid. 
Harzianic acid has an intriguing structure, which includes a tetramic acid group in its N-
methylserine-derived heterocycle.  
 In chapter 6, we discuss about a synthetic path of new heterocyclic scaffolds as structural 
analogues of natural nucleic bases. In particular, we focus on 1,4 dihydro[1,2,4]triazolo[5,1-
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c][1,2,4]triazine as a core structure and we develop a general method for the synthesis of this ring 
system that might be amenable to the preparation of 3,7-diaryl-substituted derivatives. 
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CHAPTER 3 
 
IMPROVED SYNTHESIS OF FARINOMALEIN AND ITS ANALOGUES 
AND THEIR EVALUATION FOR BIOLOGICAL ACTIVITY 
3.1 Introduction 
N
O
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O
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2. R=CH3
Farinomalein (1)
 
Farinomalein (1) 3-(3-Isopropyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)-propionic acid is a relatively 
structurally simple maleimide, recently isolated in 2009 from the entomopathogenic fungus 
Paecilomyces farinosusn HF599, by Nihira et.al.1 Entomopathogenic fungi are well known for their 
ability to produce various compounds during infection and proliferation in insects2-4 and thus are 
considered as potential sources of novel bioactive compounds.5-7 Those belonging to the genus 
Paecilomyces have been the source of wide range of bioactive metabolites, including the 
antimalarial and antitumor cyclohexadepsipeptide paecilodepsipeptide A from P.cinnamomeus,8 an 
antibiotic containing a tetramic acid moiety (paecilosetin from P. farinosus9) and neuritogenic 
pyridine alkaloids (farinosones A-C and militarinones A-D form P.militaris, respectively10,11). 
During a screening for a compound active against plant pathogenic oomycetes, the EtOAc extract of 
P. farinosus HF599 showed strong inhibitory activity against Phytophthora sojae.12 Detailed 
investigation of the fungal extract led tot the identification of the new maleimide compound 
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farinomalein (1). Reports of natural compounds bearing maleimide rings are very limited. Examples 
include showdomycin from Streptomyces showdoensis, pencolide from Penicillium multicolor, and 
turrapubesin from the twigs and leaves of Turraea pubescens.13-15 
 The structure of farinomalein contains two functional groups: -COOH and -N(CO)2; it shows 
five aliphatic carbons (one of them bonded to nitrogen), two carbon in the olefinic region, and two 
carbonyl carbon. C-2 and C-3 complete the maleimide core which is substituted with an isopropyl 
group at C-2. High resolution ESITOFMS revealed an [M + Na]+ at m/z 234.0710, corresponding to 
the molecular formula C10H13NO4. The 1H and 13C NMR spectroscopic data were in agreement with 
the assigned molecular formula. The 13C NMR spectrum of farinomalein showed 10 signals, 
indicating five aliphatic carbons (one of them bonded to nitrogen), two carbons in the olefinic 
region, and two carbonyl carbons.  
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3.2 Biological activity 
Farinomalein shows potent inhibition of Phytophthora sojae, a plant pathogen that causes 
every year enormous damage to soybean crops,2 with an MIC value of 5µg/disk, whereas the MIC 
of the antifungal agent amphotericin B is 10µg/disk. Recently, maleimides such as N-
methylmaleimide, N-ethylmaleimide, and phenylmaleimide PM-20 have attracted the interest of 
many researchers due to their cytotoxicity towards tumor cell lines through the inhibition of human 
topoisomerase II16 or the inhibition of Cdc25A.17 These facts suggested that, in addition to its potent 
antioomycete activity, farinomalein could also possess other biological functions, such as 
cytotoxicity toward tumor cell lines. 
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3.3 Reported Synthesis of farinomalein 
Recently, a three-step synthesis of Farinomalein has been reported by Miles and Yan.18 The 
sequence is based on the reaction of isovaleraldehyde 3 and glyoxylic acid 4 to give a γ-
hydroxybutenolide 2 (Scheme 1). Successive oxidation to the corresponding anhydride 5 and 
treatment with β-alanine afforded Farinomalein. However, the Authors themselves state that their 
synthesis is difficult to scale-up 18 due to the use of the hazardous and expensive oxidant Dess-
Martin periodinane. The use of this reagent was necessary to obtain a reasonable yield, because 
some of the more common oxidants (PCC and KMnO4) typically gave only moderate yields of 
anhydride 5 which was difficult to purify. On the contrary, the Dess-Martin periodinane oxidation 
proceeded cleanly and the removal of the excess Dess-Martin periodinane and of its side products 
was readily accomplished by a simple hexane extraction. 
Herein we report a different synthetic approach to Farinomalein, developed in four steps with high 
yield and without using any hazardous chemical. Our retrosynthetic approach is shown is Scheme 2, 
The key intermediate 5 can be constructed by dehydration of cis -diacid 6, on its turn obtained by 
condensation of commercially available ethyl 3-methyl-2-oxobutyrate 7 and triethyl 
phosphonoaceate 8 in the Horner Wadsworth-Emmons conditions. 
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Scheme 1 Reported Synthetic route 
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3.3.1.Retrosynthetic Approach 
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3.3.2 Synthesis of Farinomalein  
For the preparation of 3-isopropyl-furan-2,5-dione (5) we used the procedures described by 
Watanabe.19 In this synthetic path we condensed commercially available ethyl 3-methyl-2-
oxobutyrate 7 with triethyl phosphonoacetate 8 in the Horner Wadsworth-Emmons19 conditions, 
with NaH as a base and dry THF as a solvent. The reaction was carried out at 0 oC for 5 min and 
then the reaction mixture was slowly warmed to 50 oC for 2 h. After purification 80 % of the 
desired product 2-isopropyl-but-2-enedioic acid diethyl ester 920 was obtained as a faint yellow oil. 
The product was fully characterized by 1H-NMR, and 13C-NMR. The olefinic proton at C-3 
resonates at δ 5.8, whereas the coupling constant (J) of 1.17 Hz confirmed the cis configuration. 
Hydrolysis of diester 9 was carried out by using 2N LiOH in the presence of THF as a solvent. The 
reaction mixture was stirred for 8h at rt, then  acidic workup gave crude 2-isopropyl-but-2-enedioic 
acid21 6 as a colourless oil in 96 % yield. Analysis of 1H-HMR, and 13C-NMR confirmed the 
structure of diacid. The crude diacid without further  purification was treated with 10 eq of 
trifluoroacetic acid by overnight stirring at rt, to provide 3-isopropyl-furan-2,5-dione 522 as a shiny 
blackish brown oil in quantitative yield. Disappearance of the protons of diacid in 1H-NMR spectra 
confirmed the formation of an anhydride. Finally 5 was refluxed with 1 eq of β-alanine in the 
presence of AcOH19,23 for 2 h. After ethyl acetate workup and column chromatography purification 
by using diethyl ether and hexane as eluent, 1 was obtained as a white solid in 60 % yield. The 
spectroscopic data, including 1H-NMR, 13C-NMR and MS Spectra of the synthetic farinomalein, 
matched with those reported in the literature for the natural compound, thus confirming its structure. 
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Scheme 2 Improved synthetic route  
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Reagents and conditions : 
a) NaH, THF, 0 o C-50 o C, 1 h, 80%; b) 2N LiOH, THF, rt, 8h, 96%; c) TFAA, rt, overnight, quant; 
d) β-Alanine, AcOH, reflux, 1.5h, 60% 
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3.4 Synthesis of analogues   
 We scaled up the developed synthetic route up to 10 g batches, which appeared less 
expensive and non hazardous. Having the final product farinomalein in our hands, we prepared a 
number of analogues which can be useful for determination of structure-activity relationship (SAR) 
for these compounds. Also the optimised reaction conditions might be helpful for the modification 
of natural farinomalein into new synthetic fungicides. 
 In order to modify the natural farinomalein it was important to take an overview on the 
development of new natural compounds bearing maleimide rings. 
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3.4.1 Natural compounds bearing maleimide rings. 
3.4.2 Pencolide from Penicillium multicor  
 A new nitrogen-containg product, pencolide,24 obtained from the culture fluid of a strain of 
Penicillium multicolor Grigorieva Manilova and Poradielova, grown on Raulin Thom medium, was 
reported by Birkinshaw14et al. in 1963 (A). The E configuration was subsequently assigned to the 
double bond on the basis of NMR arguments (B); however Olsen and collaborators have revised the 
geometry to Z in a recent publication. It was suggested (A) that biosynthetic precursor of pencolide 
might be citraconic acid and threonine or a related amino acid. 
N
O
O
O
OH
H
N
O
O
O
OH
H
Fig. 2.1
(A) (B)
 
Pencolide was first synthesized by Strungz and Ren25 in 1975 from citraconic anhydride and 
threonine. Evidence is presented which corroborates the Z configuration. 
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3.4.3 Turrapubesin B  
Turrapubesin B,26 (fig 2.2), a maleimide bearing limonoid, was isolated from the twigs and leaves 
of Turraea pubescens by Yue and et al, in 2006. Limonoids are a class of highly oxygenated 
nortriterpenoids, either containing or derived from a precursor with a 4,4,8-trimethyl-17-
furanylsteroid skeleton, and present a wide range of biological activities, such as insect antifeeding, 
antibacterial, antifungal, antiviral, antimalarial and anticancer properties. 27 The plants belonging to 
the families of Meliaceae and Rutaceae are rich sources of these fascinating metabolites. Previous 
studies on the genus of Turraea have afforded a series of protolimonoids and limonoids.28 The plant 
material of T. pubescens has been used in the remedies of dysentery, pharyngolaryngitis, and 
traumatic hemorrhage29. Turrapubesin B is the first example of maleimide bearing limonoids in 
nature. 
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Fig. 2.2
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3.4.4 Showdomycin   
Showdomycin30 (fig. 2.3) is a broad spectrum antibiotic, first isolated from Streptomyces 
showdoensis by Nishimura and his coworkers31, in 1964 (1). The antibiotic has been found to 
exhibit definite activity against Ehrlich ascites tumor in vivo and against cultured HeLa cells. The 
structure has now been elucidated as a new class of C-nucleoside. Showdomycin consist of a 
maleimide portion and a furanose group bearing two cis vicinal hydroxyl groups. Both the sugar 
and the base moieties are linked with C-C bond. 
 
H
N
O
O
O
HO
HO
OH
(1)
Showdomycin
Fig. 2.3
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3.4.5 N-methylmaleimide, N-ethylmaleimide and PhenylmaleimidePM 20. 
Maleimide, N-ethyl-maleimide (NME), and N-methyl-maleimide (NMM) (fig. 2.4) were identified 
as potent catalytic inhibitors of purified human topoisomerase IIα32, whereas the ring analog 
succinimide was completely inactive. Catalytic inhibition was not abrogated by topoisomerase II 
mutations that totally abolish the effect of bisdioxopiperazine compounds on catalytic inhibition, 
suggesting a different mode of action by these maleimides. Furthermore, in DNA cleavage assay 
maleimide and NEM could antagonize etoposide-induced DNA double strand breaks. In a 
clonogenic assay maleimide antagonized the cytotoxicity of etoposide and daunorubicin on four 
different cell lines of human and murine origin. NMM and NEM have been extensively used for 
enzyme modification and labelling by reaction with the SH group of cysteine residues by Michael 
addition, thereby alkylating these. 
NH
O
O
N
O
O
N
O
O
maleimide N-methyl-maleimide N-ehtyl-maleimide
Fig .2. 4
 
 In short, the knowledge of the structure, shape and physical properties of farnomalein and 
related compounds has allowed us to design the synthetic analogues in which fungicidal activity and 
stability could be improved. 
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3.5 Structure-Activity Relationship  
To determine the structure activity relationship (SAR) in farinomalein , first we decided to vary the 
side chain. Natural farinomalein possesses a side chain most probably derived from β-alanine. To 
elucidate the role of side chain in the antifungal activity we have synthesized unnatural farinomalein 
analogues using different amino acid as side chain (Part A). 
 
N
O
O O
OH
Part A
Fig .2. 5
 
Accordingly, we have chosen L-leucine, L-phenylalanine, L-valine and glycine acids to 
build the side chain. The common intermediate 5 was reacted with these commercially available 
amino acids to obtained analogues 10, 11, 12 and 13 with different alkyl chains on the maleimide 
skeleton (fig. 2.6). 
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3.6 Synthesis of analogues  
For the synthesis of compound 10, we used the synthetic route already described in scheme 2. The 
common intermediate 5 was treated with glycine using AcOH and refluxed for 1.5 h, to give (3-
Isopropyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)-acetic acid (10) in 57 % yield (Scheme 3). Similarly 
other analogues,  2-(3-Isopropyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)-3-methyl-butyric acid (13), 2-
(3-Isopropyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-4-methyl-pentanoic acid (11), 2-(3-Isopropyl-2,5-
dioxo-2,5-dihydropyrrol-1-yl)-3-phenyl-propionic acid (12), were synthesized by using L-valine, L-
leucine, and L-phenylalanine respectively in 55 -60 % yields (Scheme3) 
 
 
Scheme 3 
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H OH
O
R
10  R = H
13  R = CH(CH3)2
11  R = CH2CH(CH3)2
12  R = CH2Ph
5
AcOH, reflux, 1.5h
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3.7 Evaluation of Fungicidal Activity 
3.7.1 Bioassay evaluation 
As the activity of Farinomalein against Phytophthora sojae is already documented in the literature1, 
we decided to assess the activity of farinomalein against Cladosporium cladosporioides, a fungal 
plant pathogen that affects wheat, using the method of bioautography.33,34 (Table 2.1).  
For the antifungal assay 10.0 µL of solutions corresponding to 50.0, 40.0, 30., 20.0, 10.0, 
5.0, 1.0, 0.5, and 0.1 µg were applied to precoated Si gel TLC plates. The chromatograms were 
sprayed with a spore suspension of Cladosporium cladosporioides in CZAPEK broth and incubated 
for 72h in darkness in a moistened chamber at 25 oC, following a previously reported procedure.34,35 
Fungal growth inhibition appeared as clear zones against a dark background (fig 8), indicating the 
minimum amount of compounds required for it (table). Prochloraz was used as control. 
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3.7.2 Results and discussion 
 Antifungal activities of compounds 1, 10, 11, 12, and 13, were evaluated against 
Cladosporium cladosporioides. 
12
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Fig . 2.7
 
Fig. 2.7 Farinomalein and analogues 
 The antifungal test result of all the tested compounds and their structural characteristics 
clearly offered a structure-activity relationship which is summarized as follows.(table 2.1) 
1. The bioassay results confirmed that Farinomalein is endowed with antifungal activity also 
on Cladosporium cladosporioides and likely on other plant pathogens. 
2. The minimum amount required for the inhibition of fungal growth on thin-layer 
chromatography plates was 5µg.  
  
77 
3. Moreover, the results clearly indicate that the introduction of different chains was 
detrimental for activity. In fact, the minimum amount of compounds 10, 13, 12 required for 
fungal growth inhibition was 6-10 fold higher than for 1 (30-50 µg). Branched amino acid 
are not crucial for antifungal activity. 
4. The compound 11, the analogue with L-leucine, had a moderate activity at 20 µg, showing 
that increasing the no. of carbons in the side chain may give good activity. 
 
 
 
 
Fig . 2.8 Fungal growth inhibition as clear zones. 
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Table 2.1. Antifungal activity of Farinomalein 
and analogues 
Compound 
Antifungal activity (µg)a 
C. cladosporioides 
1 5 
10 50 
12 50 
11 20 
13 50 
Prochloraz 0.1 
a Minimum amount required for the inhibition 
of fungal growth on thin-layer chromatography 
plates (TLC) 
 
3.8 Conclusion 
A practical and convenient synthesis of the fungicidal natural compound Farinomalein was 
described starting from readily available ethyl 3-methyl-2-oxobutyrate and triethyl 
phosphonoacetate, employing a Horner-Wadsworth-Emmons condensation as the key step. The 
antifungal activities of a series of analogues of farinomalein were evaluated against Cladosporium 
cladosporioides. Changing the linear side chain into a branched one are not crucial for antifungal 
activity, but increasing the no. of side chain carbon may be effective. Taking into consideration the 
result of this study, new synthetic analogues can be designed and synthesized for improving the 
antifungal activity of farinomalein. 
. 
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3.9 Experimental  
2-Isopropyl-but-2-enedioic acid diethyl ester (9) 
 
O OEt
O
OEt
9
 
 
To a stirred solution of NaH (60 %, 0.138 g 3.4 mmole 1eq) in THF (5 mL), a solution of triethyl 
phosphonoacetate 8 (0.77 g 3.4 mmol, 1eq) in THF(15.5 mL) was added at 0 oC, stirred for 30 min 
at 0 oC. To this reaction mixture ethyl 3-methyl-2-oxobutyrate 7 ( 0.51 ml 3.4 mmole ) was added at 
0 oC and stirred for 5 min at 0 oC, then the reaction mixture was slowly warmed to 50 oC for 2 h. 
Saturated aqueous NH4Cl (10 mL) was added and the aqueous phase was extracted with diethyl 
ether (3 x 30 mL). The combined organic layers were dried (Na2SO4), filtered, and concentrated. 
The residue was purified by flash column chromatography (7 % EtOAc in hexane), to afford 9 
(0.590 g 79.%) as a faint yellow oil. Rf = 0.42 (EtOAc / hexane 7:93), 
 
1H NMR (300 MHz, CDCl3) δ: 5.80 (d, J = 1.2 Hz, 1H), 4.12 (q, J = 7.2 Hz, 2H), 4.31 (q, J = 7.2 
Hz, 2H), 2.65 (m, 1H), 1.32 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H), 1.15 (d, J = 7.0 Hz, 6H).  
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2-Isopropyl-but-2-enedioic acid (6) 
 
 
O OH
O
OH
6
 
To the stirred solution of 9 (0.405 g, 1.8 mmole) in THF (21 mL) was added 2N LiOH (16 eq, 0.634 
g in 7 mL H2O) at 0 oC, then the reaction mixture was stirred for 8 h at RT. THF was removed 
under vacuum, the aqueous reaction mixture was acidified with 1N HCl (~30 mL) at 0 oC. The 
aqueous phase was extracted with ethyl acetate (3 x 40 mL). The combined organic layers were 
dried (Na2SO4), filtered, and concentrated, to obtain 6 as a colourless oil (0.286 g, 96 %). This 
crude product was used for the next reaction. Rf = 0.43 (EtOAc / hexane 50:50),  
1H NMR (300 MHz, CDCl3) δ: 8.60 (brs, 2H), 5.85 (s, 1H), 2.65-2.80 (m, 1H), 1.20 (d, J = 7.0 Hz, 
6H). 
 
  
 
 
 
 
  
81 
3-Isopropyl-furan-2,5-dione (5) 
 
 
O
O
O
5
 
In trifluoroacetic anhydride (2.56 mL, 10 eq), 6 (0.289 g) was stirred overnight at RT. The resulting 
solution was evaporated under vacuum to provide 5 as a blackish brown oil (0.245 g, 98 %), Rf = 
0.34 (EtOAc/hexane 7:93). The crude product was used for the next reaction. 
1H NMR (300 MHz, CDCl3) δ 6.51 (s, 1H), 2.80-3.00 (m, 1H), 1.2 (d, J = 7.0 Hz, 6H). 
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3-(3-Isopropyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionic acid (1) 
 
N
O
O O
OH
1
 
 
To the stirred solution of 5 (0.100 g 0.71 mmol) in AcOH (0.5 mL) β-alanine (0.063 g, 0.71 mmol) 
was added at room temperature. The reaction mixture was refluxed for 2 h, then cooled to 60 oC and 
the solvent was evaporated under vacuum. To the crude product EtOAc (10 mL) was added and the 
organic layer was washed with 2N HCl (5 mL) and brine, then dried over Na2SO4 and concentrated. 
Purification by flash column chromatography afforded 1 as a white solid (0.089 g, 60 %). m.p. 76 
°C, Rf = 0.36 (diethyl ether/hexane 50:50).  
 
1H NMR (300 MHz, CDCl3) δ: 6.25 (d, J = 1.8 Hz, 1H), 3.80 (t, J = 7.0 Hz, 2H), 2.80-2.95 (m, 
1H), 2.70 (t, J = 7.0 Hz, 2H), 1.21 (d, J = 6.9 Hz, 6H).  
 
13C NMR (CD3OD) ) δ: 173.2, 171.0, 170.8, 155.7, 124.5, 33.3, 32.2, 25.6, 19.7.  
Anal. Calcd for C10H13NO4: C 56.86; H 6.20; N 6.63. Found: C 56.98; H 6.10; N 6.51. 
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(3-Isopropyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-acetic acid (10) 
 
N
O
O
OH
O
10
 
To the stirred solution of 5 (0.050 g 0.35 mmol) in AcOH (0.5 mL) glycine (0.026 g, 0.35 mmol) 
was added at room temperature. The reaction mixture was refluxed for 2 h, then cooled to 60 oC and 
the solvent was evaporated under vacuum. To the crude product EtOAc (10 mL) was added and the 
organic layer was washed with 2N HCl (5 mL) and brine, then dried over Na2SO4 and concentrated. 
Purification by flash column chromatography afforded 10 as a oil.  
 
Yield 57 %, Rf = 0.4 (diethyl ether/hexane 50:50).  
 
1H NMR (300 MHz, CDCl3) δ: 7.80 (brs, 1H), 6.30 (s, 1H), 4.28 (s, 2H), 2.75-2.95 (m, 1H), 1.20 (J 
= 7.0 Hz, 6H) 
13C NMR (75 MHz, CDCl3) δ: 172.5, 170.3, 169.9, 156.5, 125.0, 38.3, 26.0, 20.8.  
Anal. Calcd for C9H11NO4: C 54.82; H 5.62; N 7.10. Found: C 55.01; H 5.41; N 7.01. 
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2S-(3-Isopropyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-4-methyl-pentanoic acid (11) 
 
N
O
O
H
HO
O
11
 
To the stirred solution of 5 (0.100 g 0.71 mmol) in AcOH (0.5 mL) L-leucine (0.093 g, 0.71 mmol) 
was added at room temperature. The reaction mixture was refluxed for 2 h, then cooled to 60 oC and 
the solvent was evaporated under vacuum. To the crude product EtOAc (10 mL) was added and the 
organic layer was washed with 2N HCl (5 mL) and brine, then dried over Na2SO4 and concentrated. 
Purification by flash column chromatography afforded 11 as an oil.  
Yield 53 %, Rf = 0.3 (diethyl ether/hexane 50:50). 
 
1H NMR (300 MHz, CDCl3) δ: 6.28 (s, 1H), 4.75 (dd, J = 4.6, 11.3 Hz, 1H), 2.80-2.95 (m, 1H), 
2.20-2.32 (m, 1H), 1.80-1.95 (m, 1H), 1.35-1.50 (m, 1H), 1.20 (d, J = 7.0 Hz, 6H), 0.90 (d, J = 7.0 
Hz, 6H).  
13C NMR (75 MHz, CDCl3) δ: 175.9, 170.6, 170.3, 156.1, 124.9, 50.3, 37.0, 25.9, 25.2, 23.1, 21.0, 
20.8 (x 2).  
Anal. Calcd for C13H19NO4: C 61.64; H 7.56; N 5.53. Found: C 61.39; H 7.87; N 5.31. 
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2-(3-Isopropyl-2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-3-phenyl-propionic acid (12) 
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O
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To a stirred solution of 5 (0.05 g 0.35 mmol) in AcOH (0.5 mL) L-phenylalanine (0.06 g, 0.35 
mmol) was added at room temperature. The reaction mixture was refluxed for 2 h, then cooled to 60 
oC and the solvent was evaporated under vacuum. To the crude product EtOAc (10 mL) was added 
and the organic layer was washed with 2N HCl (5 mL) and brine, then dried over Na2SO4 and 
concentrated. Purification by flash column chromatography afforded 12 as an oil.  
Yield 64 %, Rf = 0.6 (diethyl ether/hexane 50:50).  
 
1H NMR (300 MHz, CDCl3) δ: 7.10-7.30 (m, 5H), 6.12 (s, 1H), 4.98 (dd, J = 6.3, 10.5 Hz,1H), 
3.40-3.55 (m, 2H), 2.68-2.80 (m, 1H), 1.18 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 7.0 Hz, 3H).  
13C NMR (75 MHz, CDCl3) δ: 174.5, 170.2, 169.9, 155.9, 136.5, 129.0 (x 2), 128.7 (x 2), 127.0, 
124.5, 52.9, 34.4, 25.8, 20.7. 
Anal. Calcd for C16H17NO4: C 66.89; H 5.96; N. 4.88. Found: C 66.55; H 6.12; N. 4.65. 
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2-(3-Isopropyl-2,5-dioxo-2,5-dihydropyrrol-1-yl)-3-methyl-butyric acid (13) 
 
N
O
O
H
HO
O
13
 
To the stirred solution of 5 (0.05 g 0.35 mmol) in AcOH (0.5 mL) L-valine (0.041 g, 0.35 mmol) 
was added at room temperature. The reaction mixture was refluxed for 2 h, then cooled to 60 oC and 
the solvent was evaporated under vacuum. To the crude product EtOAc (10 mL) was added and the 
organic layer was washed with 2N HCl (5 mL) and brine, then dried over Na2SO4 and concentrated. 
Purification by flash column chromatography afforded 13 as an oil.  
 Yield 41 %, Rf = 0.5 (diethyl ether/hexane 50:50).  
 
1H NMR (300 MHz, CDCl3) δ: 9.00 (brs, 1H), 6.25 (s, 1H), 4.40 (d, J = 8.4 Hz, 1H), 2.80-2.95 (m, 
1H), 2.60-2.75 (m, 1H), 1.20 (d, J = 7.0 Hz, 6H), 1.10 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 7.0 Hz, 3H).  
 
13C NMR (75 MHz, CDCl3) δ: 174.3, 170.6, 170.3, 156.0, 124.7, 57.6, 28.4, 25.9, 20.8 (x3), 19.5. 
Anal. Calcd for C12H17NO4: C 60.24; H 7.16; N 5.85. Found: C 60.66; H 7.00; N 5.57. 
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CHAPTER 4 
 
Epicoccamide D 
4.1 Introduction 
3-Acyltetramic acids1,2 (3-acylpyrrolidine-2,4-diones) are core structural skeletons that have been 
found in various naturally occurring biologically active products. In recent years, the chemistry of 
tetramates has experienced a renaissance instigated by a steadily increasing number of isolated 
natural products of this type with distinct biological activities.5 The structurally complex6 3-
acyltetramic acids are among the most commonly found biologically active products such as 
magnesidein A (antibiotic activity),7a reutericyclin (antibiotic activity),7b tenuazonic acid (antiviral 
and antitumor activity),7c Sch 213766 (anti-HIV activity),7d and  the melophins (antitumor),7e and 
the macrocidins (herbicidal activity)7f (Fig.1) 
Fig 1. Examples of naturally occurring 3-acyltetramic acids. 
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Three new tetramic acid derivatives, epicoccamides B-D, have recently been isolated from an 
Epicoccum sp. associated with the tree fungus Pholiota squarrosa, in 2007 by Hertweck et al.3  In 
2003 Konig4 and co-workers isolated epicoccamide (A) from the inner tissue of the jellyfish Aurelia 
aurita, a marine strain of the fungus Epicoccum purpurascens. 
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Epicoccamides are quite unusual since they are composed of three biosynthetically distinct 
subunits; glycosidic, fatty acid and tetramic acid. The structures of the new compounds were 
elucidated on the basis of their physical data and chemical degradation. Epicoccamides B-D, differ 
in substitution pattern and in the size of the central carbon chain. The main metabolite 
“epicoccamide A” (1) proved to be identical with an unusual tetramic acid glycoside.4 The 1H-NMR 
spectrum of 2 was similar to that of 1, except for the presence of an additional singlet at δ 2.16 (3H, 
s, H-8’). Also in the 13C NMR spectrum additional resonances were observed at δ 21.0 (CH3) and 
171.2 (C=O), suggesting that 2 is an O-acetyl derivative of 1. The sugar moiety was identified as β-
mannose with D configuration. Thus, 2 was identified as 5-hydroxy-1,2-dimethyl-4-[2-methyl-16-
(3-O-acetyl-β-D-mannopyranosyl)hexadecanoyl]-1H –pyrrol-3(2H)-one (epicoccamide B). Its 
structure was confirmed by MS/MS data, which showed the cleavage of the acyl moiety followed 
by dehydration. The molecular formula of Epicoccamide C (3) was determined by HREIMS, 
indicating that 3 is an isomer of 2. Its 1H NMR and 13C NMR spectra were almost identical with 
those of 2. The structure of 3 was elucidated as 5-hydroxy-1,2-dimethyl-4-[2-methyl-16-(6-O-
acetyl-β-D-mannopyranosyl)hexadecanoyl]-1H–pyrrol-3(2H)-one by HMBC. The UV spectrum of 
  
93 
epicoccamide D (compound 4) as well as the MS/MS fragmentation patterns suggested that 4 is a 
homologue of 1 with a mass difference of 28 units. Two ion fragments at m/z = 422.2 and 125.9 
indicated the loss of the sugar moiety and that the aliphatic chain consists of two additional 
methylene groups, a result supported by NMR data. The structure of 4 was thus elucidated as 5-
hydroxy-1,2-dimethyl-4-[2-methyl-18-β-D-mannopyranosyloctadecanoyl]-1H–pyrrol-3(2H)-one. 
 All the epicoccamides have two stereogenic centres in the aglycone portion of the molecule, but 
the absolute configuration at C-8 and C-4 could not be solved so far.  
4.2 Biological activity 
Microorganisms that live in symbiosis have proven to be a rich source of biologically active natural 
products.8 There is growing evidence that many metabolites isolated form plant and animals are in 
fact produced by microorganisms.9 The crude extract of Epicoccum sp. exhibited notable 
antiproliferative and cytotoxic activities, then all four epicoccamides were individually probed. 
Among these four compounds the derivative with the longest chain, epicoccamide D proved to be 
the most active . It exhibits weak to moderate cytotoxicity towards HeLa a cell lines (CC50 17.0µM) 
and good antiproliferative effects on mouse fibroblast (L-929) and human leukaemia cell lines (K-
562) with inhibition of growth (GI50) of 50.5 and 33.3µM, respectively. Furthermore, epicoccamide 
D induces morphogenesis and pigment formation in surface cultures of the fungus Phoma 
destructive at a concentration of 1.7 mM.  
 
4.3 Synthesis of Epicoccamide D (4) 
Compound 4 has an intriguing structure, which includes a tetramic acid group in its N-
methylalanine derived heterocycle. Numerous biologically active natural products contain the 
tetramic acid (pyrrolidin-2, 4-dione) ring system. The range of biological activities possessed by 
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individual members of this series includes potent antibiotic, antiviral, and antiulcerative properties, 
cytotoxicity and mycotoxicity, the inhibition of tumors as well as fungicidal action . Moreover, 
certain members of this class are responsible for pigmentation of some sponges and molds.1,10 The 
structural complexity, together with potent biological activity, of many tetramic acids makes the 
total synthesis of these compounds an attractive goal for organic chemists. The epicoccamide D has 
significant antifungal and plant growth promotion effect, which makes it a potential lead for the 
design of new antifungal. Herein, we describe the efforts towards the first total synthesis of 
epicoccamide D (4). 
 
4.4 Reported synthetic methodologies for 3-acyltetramic acids. 
Given the biological importance of this motif, various synthetics methodologies for 3-acyltetramic 
acids1,11,12 as well as tetramic acids themselves13 have been developed, and there are two main 
routes for their synthesis (fig 2). One is to incorporate the acyl group (R2) before the construction of 
the tetramic acid core,12-16 and the most common approach is by Dieckmann-type cyclization of β-
keto amide A under basic conditions.12-15 However, even though such cyclization, including solid 
phase protocols,16 has been widely applied for the synthesis of natural12-14 and unnatural15 
analogues, only N-unsubstituted and N-alkyl 3-acyltetramic acid (R1 = H, alkyl) have been prepared 
in this way, but critically not the N-acyl system found in magnesidin A and reutericyclin (R1 = 
acyl). This is likely to be due to the difficulty of accessing the required N-diacyl precursor A ( R1 = 
acyl). Importantly, the Markopoulou group has elegantly circumvented this difficulty to some 
extent by in situ C-acylation of β-keto esters and malonates with activated ester B to give precursors 
C followed by intramolecular condensation under basic condition, which established access not 
only to N-substitued and N-methyl but also some N-acyl and N-alkoxycarbonly 3-acyltetramic 
acids.16 
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The second alternative route is to incorporate the acyl group (R2) after the construction of the 
tetramic acid main core.17-19 In this matter, Jones’ group has developed a methodology involving 
base mediated (n-BuLi) condensation of 4-O-methyl tetramic acid D with aldehydes (R2CHO) to 
give hydroxyl adducts E, and oxidation followed by demethylation, under basic conditions to give 
the desired 3-acyltetramic acid.17 This method was particularly efficient for 1,5,5-trisubstituted 
tetramates D but less substituted tetramates suffered from a side reaction caused by lithiation at both 
N(1) and C(5).17b More conveniently, direct acylation at the 3-position of tetramic acid F could be 
achieved with acid chlorides (R2COCl) activated by Lewis acid catalysts such as BF3.OEt2 and 
TiCl4,18 although with 5-unsubstituted tetramic acids, self-condensation under these conditions has 
been reported.18d Finally, their synthesis via base-induced acyl migration of O-acyltetramic acids G, 
themselves readily prepared from tetramic acids F using Kech coupling conditions in the presence 
of N, N’-dicyclohexylcarbodiimide (DCC) with a catalytic amount of 4-dimethylaminopyridine 
(DMAP),19a has been reported; for example, the in situ or stepwise acyl-migration of O-acyltetramic 
acids G induced by triethylamine,19b,c triethylamine with hydroxybenzotriazole,19d or acetone 
cyanohydrin 19c is possible. Schobert et al19c reported the synthesis of tetramic acid main core from 
α-aminoesters or their ammonium salts; cyclization is brought about by a domino addition-Wittig 
alkenylation reaction with the cumulated phosphorus ylide (triphenylphosphoranylidene)ketene, 
Ph3PCCO, under neutral non-racemizing conditions. 
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Fig 2. Synthetic approaches to 3-acyltetramic acid 
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4.5 Convergent synthetic strategy  
4.5a Retrosynthetic Approach 
Our initial retrosynthetic analysis was based upon the construction of the acyltetramic nucleus. In 
the beginning we envisioned that epicoccamide D could be constructed by the convergent synthetic 
strategy which has been proposed by Schobert et.al.19c Our first strategy for the synthesis of 4 was 
based on the coupling of two domains: a side chain subunit 5 and N-methyl pyrrolidine-2,4-dione 
subunit 6 (Scheme 1). 
 We envisaged that the preparation of the subunit 5 could start from the O-protected long 
carbon chain acid 8 which could be easily obtained by manipulation of the commercially available 
methyl 16-bromohexadecanoate. Whereas the tetramic acid moiety, subunit 6, could be obtained by 
Wittig alkenylation reaction between phosphorus ylide (triphenylphosphoranylidene)ketene, 
Ph3PCCO and commercially available N-methyl L-alanine ammonium salt. 
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4.6 Synthesis of subunit 6  
For the preparation of the tetramic acid main core, subunit 6 (Scheme 2), we used procedures 
described by Schobert et.al.19c In this synthetic path we carried out a microwave reaction of N-
methyl L-alanine t-butyl ester, and Ph3PCCO ketene in presence of THF as a solvent, for 30 min at 
90 oC. After purification, 50 % of the intermediate 4-tert-butoxy-1,5-dimethyl-1,5-dihydropyrrol-2-
one 9 was obtained as a white solid. The product was fully characterized by 1H-NMR and 13C-
NMR. Cyclization is confirmed by the presence of an olefinic proton at δ 5.00 (s). This reaction 
suffers from a drawback, as it was difficult to remove the side product triphenylphosphane oxide 
(Ph3P=O). After column chromatography the product was washed with diethyl ether to remove 
triphenylphosphane oxide. The detert-butoxylation of intermediate 9 was carried out by using 
trifluroaceticacid (TFA) as a dehydrating agent, to quantitatively yield 1,5-dimethyl-pyrrolidine-
2,4-dione 6. (Scheme 2). The spectroscopic data, including 1H NMR and 13C NMR confirmed the 
structure. Disappearance of the protons of tert-butoxy group and appearance of a broad peak of 
keto-enol proton in 1H NMR confirmed the formation of a tetramic acid. 
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Scheme 2 
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Reagents and conditions : 
a) Microwave, THF, 120 o C, 30 min, 50 %; b) TFA, rt, 3 h, 99 %.  
 
 
4.7 Synthesis of subunit 5 
For the synthesis of fatty acid subunit 5, we planned to use a commercially available and cheap 16-
bromo hexadecanoate as a starting material. Synthesis of subunit 5 is outlined in scheme 3. Methyl 
16-bromohexadecanoate 10 was successively reduced by 2M solution of lithium aluminium hydride 
in THF, at 0 oC in the presence of diethyl ether as a solvent, to give 16-bromo hexadecanol 11 in 
almost 85 % yield. The primary alcohol 11 was protected with tetrahydropyran, reaction was 
carried out at rt for 8 h by using 3,4-dihydro-2-H pyran and  catalytic amount of PTSA in the 
presence of THF as a solvent, to obtain 12 in 90 % yield. The product was fully characterized by 1H 
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NMR and 13C NMR, where the protection of the primary alcohol was confirmed by the presence of 
the proton of tetrahydropyran at δ 4.50 (m). In order to have a methyl group on C-8 in 
epicoccamide D, at the beginning we used ethyl propionate to introduce the methyl group and LDA 
as a base following a literature procedure.20 We carried out this reaction in all possible conditions 
using THF, HMPA as  solvents but we were unable to obtain satisfactory results presumably due to 
unstable Li-enolate of ethyl propionate and solidification of 12 at cooling conditions (Scheme 3 
route 1). Therefore, in the second approach we used a procedure described by Omura Satoshi21 and 
co-workers, who used diethyl methylmalonate as a methyl source, with sodium hydride as a base 
and DMF as a solvent. The intermediate 15 was thus obtained in 85 % yield as an oil. The 
spectroscopic data, including 1H-NMR and 13C-NMR confirmed the structure. Appearance of a new 
peak at δ 4.10 (4H, q) indicated the presence of the methylene group of two ethyl ester group. 
Further one ethyl ester group was successively removed by Krapcho decarboxylation reaction, 
using 2eq of lithium chloride and DMSO as a solvent. We were able to obtain intermediate 13 in 50 
% yield as an oil (Scheme 3, route 2). The product was fully characterized by 1H-NMR and 13C-
NMR, where the decreased number of protons in 1H-NMR at δ 4.10 (2H, q) confirmed the structure 
of 13. Further hydrolysis of ester 13 was carried out by using 5eq of potassium hydroxide in 
ethanol-water at 80 oC for 5 h, to give after acidic workup 14 as a colourless oil in 80 % yield. 
Analysis of 1H-HMR, and 13C-NMR confirmed the structure. In the next step for conversion of acid 
14 to acyl chloride 5 we used either thionyl chloride or oxalyl chloride, but unfortunately after 
several attempts we were not able to obtain acyl chloride 5. Instead, we obtained a O-deprotected 
side product with a number of other impurities, presumably due to the use of acidic condition. So 
we were unable to use the acyl chloride 5 for further transformation in order to complete the total 
synthesis of epicoccamide. Work is still in progress to obtain the  conversion of 14 to 5. 
 
 
  
102 
 
Scheme 3 
OBr
O
OHBr OBr O
O OO
O
O OHO
O
O OCl
O
OBr O
O
OEt
O
OEt
O O
O
EtO
OEtO
O OO
O
O OHO
O
O OCl
O
14 14 14
141414
11
12
13
14
10
5
Route 1
Route 2
14
12
+
14
15
14
13
14
14
14
5
a b
c
d
e
f
  
Reagents and conditions : 
a) 2M LAH in THF, diethyl ether , 0o C, 45 min, 85 %; b) 3,4-dihydro-2H-pyran, THF, PTSA, rt, 8 
h, 90 %; c) 1.8M LDA, ethyl propionate, THF, -78oC to -30 oC; d) NaH, Diethyl methylmalonate, 
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DMF, 0oC to rt, 4 h, 81 %; e) LiCl, DMSO, H2O, reflux, 12 h, 55.5 %; f) KOH, EtOH, reflux, 5 h, 
70 %. 
 
Looking for a more direct approach, we decided to follow the base-induced acyl migration of O-
acyltetramic acids G (fig 2), readily prepared from tetramic acids F using Keck coupling condition 
in the presence of N, N’-dicyclohexylcarbodiimide (DCC) with a catalytic amount of 4-
dimethylaminopyridine (DMAP).19a Moreover, the in situ or stepwise acyl-migration of O-acyl 
tetramic acids G induced by triethylamine,19b,c triethylamine with hydroxybenzotriazole,19d or 
acetone cyanohydrin 19c has been reported. Both the subunits 14 and 6 were in our hand. Coupling 
of the two halves of the molecule was achieved by Keck coupling. We carried our this reaction at rt 
for 5h in the presence of DCC with a catalytic amount (0.1 equiv) of DMAP.19c We obtained 16 
(Scheme 4) in 40 % yield, and spectroscopic data including 1H-NMR and 13C-NMR confirmed the 
structure. The presence of an olefinic proton at δ 6.00 (1H, s) of C-2 confirmed the coupling. With 
the O-acyl derivative 16 in hand, Fries-type migration of the O-acyltetramic acid using a catalytic 
amount (0.5 eq.) of acetone cyanohydrin in the presence of triethylamine (2.0 eq) in acetonitrile, 
according to the previous reported19e was then tried. Unfortunately, by this method we were not able 
to obtain the migrated product 17, thus we decided to carry out the procedure reported by 
Schobert.19c Using triethylamine as a base in DCM, after overnight stirring at rt we were able to see 
a new polar spot on TLC together with unreacted starting material. When for completion of the 
reaction we stirred the reaction mixture for another 12 h, after concentration of reaction mixture, the 
new polar spot on TLC had disappeared and converted to starting material. Therefore, for 
confirmation of this reversible reaction we decided to use other bases such as DIPEA, DMAP, but 
we observed the same reaction pattern. The yield with this method is strongly dependent on the 
identity of the carboxylic acid (R2 group) but not on the nature of R1 substituent at N(1) (fig 1), thus 
the reactions with aromatic and α-olefinic carboxylic acids are better.22 This Fries-type 
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rearrangement approach has been widely used in tetronic acid synthesis,24 but it has been much less 
widely applied in tetramates23,19c and in particular its suitability for N-acyltetramic acids has not 
been studied. Moreover, Hori19b indicates that although this reaction in a stepwise manner in one 
pot by formation of the kinetic O-acylated enol followed by acyl migration after the addition of 
triethylamine gives very high yields of 3-alkanoylation for N-unsubstituted and N-alkyl system, it is 
less efficient for unsubstituted acids. In fact, the effect of the R1 and R2 substituent’s on this 
reaction sequence has not been studied in detail. Unfortunately, we were not able to obtain the 
migrated product 17 from 16 after several attempts using different base and reaction condition.  
Scheme 4 
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Reagents and conditions : 
a) DCC, DMAP, DCM, 0 oC to rt , 5 h, 40 %; b) TEA, DCM. 
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As we were unable to obtain intermediate 17, we decided to follow one of the synthetic 
approaches discussed in the  “reported synthetic methodologies for 3-acyltetramic acids (Fig 1)”. 
Epicoccamide D could be synthesized by a linear synthetic strategy, the most common approach of 
which is a Dieckmann-type cyclization of β-keto amide A (fig. 1) under basic conditions.12-16 
Considering the above fact, we revised the retrosynthesis again, as depicted in Scheme 4. The 
disconnection identified fragment 18, which could be constructed by acid-amine coupling of 
intermediate β-ketoacid 19 and N-methyl L-alanine t-butyl ester. The β-keto acid 19 can be obtained 
by hydrolysis of β-keto ester 20, which could be constructed by oxidation of β-hydroxy ester 21. On 
its turn 21 could be constructed by Zn-activated Reformatsky coupling of aldehydes 22 and ethyl 
bromoacetate. 
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4.8 Liner synthetic strategy   
To follow the linear synthetic strategy we decided to carry out the above reaction sequence with 
another substrate which structurally resembles 22 in order to set the reaction conditions and to avoid 
loss of aldehyde 22 (Scheme 5). Considering the above facts we started with commercially 
available ester 23 which is a model for 16-bromohexadecanoate 10. Reduction of ester 23 with 2M 
LAH in THF and diethyl ether as solvent for 1 h at 0 oC gave the hydroxy intermediate 24, which 
was then oxidized by PCC in DCM after overnight stirring at rt to provide aldehyde 25. All these 
products were purified by column chromatography and fully characterized by 1H-NMR. Finally the 
condensation of aldehyde 25 with ethyl bromoacetate using metallic zinc25 in presence of benzene 
as a solvent afforded β-hydroxyester 26, whose structure was confirmed by spectroscopic data 
including 1H-NMR. Further oxidation of 26 with PCC in DCM afforded β-keto-ester 27. Further we 
wanted to hydrolyze ester 27 to β-keto-acid 28, in order to couple it with N-methyl L-alanine t-butyl 
ester. For this hydrolysis we tried KOH and LiOH and other reaction conditions and solvents but 
unfortunately we were not able to obtain intermediate 28. Conversely, the decarboxylated 
intermediate 30 was obtained. After several attempts, we used AcOH and few drops of HCl for 
hydrolysis of 27. After 48 h stirring at rt and workup with diethyl ether we were able to obtain β-
keto-acid 28, structurally confirmed by 1H NMR. This result indicated that some changes had to be 
made in the synthetic strategy, as in the desired compound we have the acid sensitive OTHP group 
and we cannot use such strong acidic condition for hydrolysis.  
 Now both keto-acid 28 and N-methyl L-alanine t-butyl ester were in our hands. So we tried a 
acid-amine coupling by using as  coupling reagents DCC and HOBT in presence of TEA and DCM 
as a solvent. Even after overnight stirring at rt we were not able to obtain the desired intermediate 
29. The TLC of this reaction was complex, but purification of the main spot gave the 
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decarboxylated intermediate 30. This result means that the hydrolysis of the β-keto-ester favours the 
decarboxylation. 
Scheme 5 
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Reagents and conditions : 
a) 2M LAH in THF, diethyl ether , 0o C, 45 min, 90 %; b)  PCC, DCM, rt, 8 h, 88 %; c) Zn, 
benzene, ethyl bromoacetate, 80 oC, 5 h. 88 %; d) PCC, DCM, rt, 7 h, 72 %; e) AcOH, HCl, 48 h,  
f) KOH, EtOH, reflux, 5 h; g) DCC, HOBT, TEA, DCM, N-methyl L-alanine t-butyl ester, rt. 
 
 As we were unable to obtain the desired intermediates 28 and 29, we decided to use β-
hydroxy-ester 26 for another synthetic approach . The sequence is depicted in scheme 6. Hydrolysis 
of intermediate 26 was easily carried out by using KOH in EtOH and H2O at rt overnight, and after 
acidic workup we obtained β-hydroxy-acid 31. Structural confirmation was done by 1H NMR. We 
successively carried out acid-amine coupling26of 31 and N-methyl L-alanine t-butyl ester by using 
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coupling reagent DCC, HOBT and base TEA in DCM to obtain 32, whose structure was confirmed 
by 1H-NMR spectra. Oxidation of 32 was attempted with oxidizing agents such as 1) IBX in DMSO 
2) supported-TEMPO, KBr, in DCM27 3) Dess-Martin28 in DCM 4) Swern oxidation and 5) 
Pyridine-SO3, in DMSO, but none of the above worked. So looking for an ester-amine coupling we 
found a literature paper29 mentioning that the ester-amine coupling can be carried out by using 
DABCO-(AlMe3)2 and TEA in dry THF at 40 oC for 1 h. We performed this reaction between β-
keto-ester 27 and N-methyl L-alanine t-butyl ester but we did not obtain the desired intermediate 34 
even after refluxing 20 hours. After all these attempts we came to the conclusion that hydrolysis of 
β-keto-ester 27 and oxidation of β-hydroxy amide are difficult. To obtain the tetramic acid core 33 
we must have β-keto-amide 29 in order to complete synthesis of epicoccamide D.  
 
 
 
 
 
 
 
  
 
 
  
110 
Scheme 6 
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Reagents and conditions : 
a) KOH, EtOH, rt, overnight, 82 %; b) DCC, HOBT, TEA, DCM, N-methyl L-alanine t-butyl ester, 
rt , overnight, 70 %; c) Oxidation. d) (AlMe3)2.DABCO, TEA, THF, reflux. 
 
As we were unable to obtain the β-keto-amide 29, we decided not to carry this synthetic 
pathway on 16-bromohexadecanoate 10. So looking for another synthetic approach toward the 
synthesis of epicoccamide D we found in literature Igglessi-Markopoulou16d report on the 
condensation of N-(N-acetylglycyloxy)succinimide with a β-keto-ester bearing alkanoyl or dienoyl 
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groups, that furnishes a 3-substituted N-acetyltetramic acids. Herein, we planned to employ the 
same strategy in our following approach. 
 The use of enolic β-dicarbonyl compounds for the synthesis of nitrogen heterocycles16c,d,e is 
another approach to synthesize the tetramic acid core. The proposed methodology is centred on the 
condensation of N-(N-acetylglycyloxy)succinimide with an excess of the anion of an appropriate β-
keto-ester, generated by the action of a strong base. Considering the above fact, we revised the 
retrosynthesis again as depicted in scheme 7. The disconnection identified the known fragments β-
keto-ester 20 and 35. The fragment 20 can be constructed by a known synthetic pathway which is 
described in scheme 5 and fragment 35 could be obtained by partial modification of the literature 
procedure16d where we planned to use 4-nitrophenol instead of N-hydroxysuccinimide. 
In order to explore the reaction conditions and to avoid loss of the expensive intermediate 20 we 
carried out this synthetic sequence by using ethyl acetoacetate instead of β-keto-ester 20 and DL-
alanine inseated of N-methyl L-alanine t-butyl ester (Scheme 8). Protection of DL-alanine carried 
out according to a literature procedure30 by using di-tert-butyldicarbonate in presence of dioxane-
water and 1N NaOH provided Boc-protected DL-alanine, which was then coupled with 4-
nitrophenol by using the coupling reagent EDCI and DCM as solvent to give compound 35, the 
structure of which was confirmed by 1H-NMR. Following the same literature procedure,16d coupling 
of 35 and ethyl acetoacetate by using NaH as a base and benzene as a solvent gave the intermediate 
36 which was fully characterized by spectroscopic data including 1H-NMR. Finally, cyclization 
with sodium ethoxide in ethanol at reflux for 3 h afforded the tetramic acid core 37. Mass spectra of 
this compound showed a peak at m/z 154 which indicated that the Boc protection had been cleaved. 
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Scheme 8 
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Reagents and conditions : 
a) (Boc)2O, 1N NaOH, H2O, Dioxane, 85 %; b) EDCI, DCM, rt, overnight, 73 %; c) NaH, DMF, 
ethyl acetoacetate, rt, 2 h, 18 %; d) NaOEt, EtOH, reflux, 3 h. 
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On the basis of the successful synthesis of tetramic acid core 37, we applied this synthetic 
strategy to compound 20, which is depicted in scheme 9. For the synthesis of the β-keto-ester we 
followed the same synthetic path which is depicted in scheme 5. We started from known 
intermediate 13 which had been synthesized from methyl 16-bromohexadecanoate 10 (Scheme 3). 
Reduction of 13 was carried out by using 2M LAH in THF and diethyl ether as solvent at 0 oC for 1 
h, to give the hydroxy intermediate 21. Oxidation with PCC in DCM provided aldehyde 22. The 
condensation of aldehyde 22 with ethyl bromoacetate using metallic zinc25 in presence of benzene 
as a solvent afforded β-hydroxy-ester 21. Finally, oxidation of 21 was carried out by overnight 
stirring at rt with PCC in DCM as a solvent to provide β-keto-ester 20 in 80 % yield. Compound 20 
was fully characterized by spectroscopic data includes 1H-NMR and 13C-NMR. 
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Reagents and conditions : 
a) 2M LAH in THF, diethyl ether , 0o C, 45 min, 95%; b) PCC, DCM, rt, 8 h, 73%; c) Zn, Benzene, 
ethyl bromoacetate, 80 oC, 5 h, 80 %; d)  PCC, DCM, rt, 7 h, 82%; e) (Boc)2O, 1N NaOH, H2O, 
Dioxane; f) EDCI, DCM, rt, overnight, 40 %; g) NaH, Benzene,  rt, 2 h, 16 %. 
 
 Compound 38 was synthesized from N-Me-L-alanine. Boc protection of N-Me-L-alanine 
using di-tert-butyldicarbonate in presence of dioxane-water and 1N NaOH provided Boc protected 
L-alanine which was then coupled with 4-nitrophenol by using coupling reagent EDCI in DCM to 
obtain compound 38, the structure of which was confirmed by 1H-NMR.  
 Now both the intermediates 20 and 38 were in our hands. Coupling of the two halves was 
achieved, according to an extension of the method proposed by Oikawa and Sugano,31 by 
condensation of 38 with an excess of the anion of the β-keto-ester 20, generated by the action of 
sodium hydride in benzene as a solvent. After purification the coupled compound 39 was obtained 
in 16 % yield. Compound 39 was fully characterized by 1H-NMR and 13C-NMR.  
 The following crucial step in this synthesis is the cyclization to the desired tetramic acid. 
Therefore having 39 in our hand we decided to carried out first the deprotection of N-Boc and then 
the cyclization. In the beginning we used AlCl3 in DCM for deprotection of N-Boc, but due to the 
strong acidic nature of AlCl3,  starting compound 39 was decomposed. As intermediate 39 is an acid 
sensitive intermediate we decided to use milder reaction condition for deprotection of N-Boc. 
Keeping this in mind we followed a literature procedure32 in which tetraammonium fluoride was 
used. We carried out this reaction in presence of THF as solvent and 5 eq of tetraammonium 
fluoride at reflux temperature for more than 7 h but we were not able to see any conversion on TLC. 
Then we tried another reported procedure33 in which deprotection of N-Boc can be carried out just 
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by refluxing with water. We performed this reaction by refluxing 39 in water but unfortunately we 
couldn’t see any progress in reaction. Even after several attempts we were unable to obtained deBoc 
intermediate 40. 
4.9 Future perspectives  
Thus the next choice for the cyclization reaction to obtain the tetramic acid core is to couple the Boc 
protected alanine 41 with 4-nitrophenol by following the same procedure to obtain intermediate 43, 
and then condense it with the β-keto-ester 20 followed by the cyclization using sodium ethoxide in 
ethanol. Finally, deprotection of N-Boc could be done by acidic medium followed by methylation 
can be achieved by using MeI (Scheme 10).  
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4.10.Conclusion 
We have successfully accomplished the synthesis of the two coupling fragments 20 and 38 required 
for the final stage of the synthesis of epicoccamide D. The proposed route is concise and modular, 
making it convenient for large scale preparation. 
 
4.10 Experimental 
 
4-tert-Butoxy-1,5-dimethyl-1,5-dihydropyrrol-2-one (9) 
 
 
 
N
O
O
9
  
 
Ph3PCCO (0.309 g 1.02 mmole, 2 eq) was suspended in THF (3 mL) and after 10 min swelling 
treated with N-Me-Ala-tert-butylester(0.100 g, 0.511 mmole). The mixture was irradiated in the 
microwave synthesizer at 90 oC for 30 min. After filtration and washing of keten with (2 x 10 mL) 
of each THF, DCM and diethyl ether crude product purified by column chromatography using 
eluent ethyl acetate. Purification by flash column chromatography afforded 9 as a pale yellow oil 
(0.038 g, 40 %). Rf = 0.38 (EtOAc ),  
 
1H NMR (300 MHz, CDCl3) δ: 5.01 (s, 1H), 3.73 (q, J = 7.2 Hz, 1H), 2.88 (s, 3H), 1.43 (s, 9H), 
1.27 (d, J = 7.2 Hz, 3H) 
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1,5-Dimethyl-pyrrolidine-2,4-dione (6) 
 
 
N
O
O
6
 
 
Tetramate 9 (0.174 mmole) was dissolved in dry TFA (0.87 mL) and stirred at rt for 3 h. n-hexane 
was added and all volatiles were removed under reduced pressure on a rotary evaporator. The 
residue thus obtained was dried on an oil pump to leave a sufficiently pure, bright yellow tetramic 
acid 6, (0.038 g, 40%). Rf = 0.38 (EtOAc). 
 
1H NMR (300 MHz, CDCl3) δ: 3.94 (q, J = 7.2 Hz, 1H), 3.31 (s, 2H), 3.01 (s, 3H), 1.40 (d, J = 7.2 
Hz, 3H) 
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16-bromo hexadecanol (11) 
OHBr
14
11
 
To a stirred solution of 10 (0.500 g, 1.43 mmol) in diethyl ether (13 mL) 2M LAH in THF (0.12g, 2 
eq, 3.6 mmol) was added at -10 oC. The reaction mixture was stirred for 1 h at 0 oC. The reaction 
was quenched with H2O at 0 oC. The aqueous phase was extracted with diethyl ether (3 x 20 mL). 
The combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash 
column chromatography afforded 11 as a floppy white solid (0.39 g 85%). Rf = 0.2 (EtOAc / 
hexane 10:90). 
1H NMR (300 MHz, CDCl3) δ: 3.64 (t, J = 6.6 Hz, 2H), 3.41 (t, J = 7.3 Hz, 2H), 1.85 (m, 2H), 
1.17-1.63 (m, 26H). 
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2-(17-Bromo-hexadecyloxy)-tetrahydropyranc (12) 
 
OBr
14
O
12
 
To a stirred solution of 11 (0.35 g, 1.1 mmol) in THF (3 mL) 3,4-dihydro 2H pyrane (0.14 g, 1.5eq, 
1.6 mmol) was added at rt followed by catalyticale amount of PTSA.H2O. The reaction mixture was 
stirred for 8 h at rt. After completion of the reaction, the mixture was evaporated under reduced 
pressure on a rotary evaporator. Purification by flash column chromatography afforded 12 as a 
floppy white solid (0.40 g, 90 %). Rf = 0.8 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.51 (t, J = 4.4 Hz, 1H), 3.86 (m,1H), 3.72 (dt, J = 9.1, 7.0 Hz, 1H), 
3.31-3.55 (m, 4H), 1.13-1.96 (m, 34H). 
 
 
 
 
 
 
 
 
 
 
 
  
123 
2-Methyl-2-[16-(tetrahydropyran-2-yloxy)-pentadecyl]-malonic acid diethyl ester (15) 
 
O
14
O
O
EtO
OEtO
15
 
 
To a suspension of NaH (60 %, 0.029 g, 1.2 mmole) in DMF (1 mL) was added dropwise Diethyl 
methylmalonate (0.077 g, 0.44 mmole) at 0 oC. After stirring for 30 min, 12 was dissolved in 1 ml 
DMF and added to above reaction mixture. The mixture was warmed to rt and stirred for 4 h. The 
reaction mixture was added sat.aq.NH4Cl solution, and the aqueous layer was extracted with diethyl 
ether. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and 
concentrated. Purification by silica gel chromatography afforded 15 as a colourless oil at rt (0.20 g, 
81 %). Rf = 0.5 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.57 (m, 1H), 4.17 (q, J = 7.3 Hz, 4H), 3.86 (m, 1H), 3.72 (m, 1H), 
3.49 (m, 1H), 3.37 (m, 1H), 0.91-1.89 (m, 43H). 
13C NMR (75 MHz, CDCl3): δ: 172.6, 98.9, 67.8, 62.4, 61.4, 61.1, 53.7, 35.5, 30.8, 29.9, 29.7, 
29.4, 26.3, 25.8, 25.6, 24.3, 19.9, 19.8, 14.1. 
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2-Methyl-18-(tetrahydro-pyran-2-yloxy)-heptadecanoic acid ethyl este (13) 
 
O14 OO
O
13
 
 
A mixture of 15 (0.085 g, 0.174 mmole), lithium chloride (0.018 g, 0.42 mmole), water (5 µL) and 
DMSO (0.5 mL) were heated at reflux for 12 h. After cooling, the mixture was diluted with brine 
and the aqueous layer was extracted with diethyl ether. The combined organic layers were dried 
over Na2SO4, filtered, and concentrated. Purification by silica gel chromatography gave 13 (0.040 g, 
55.5 %) as an oil. Rf = 0.58 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.58 (t, J = 4.25 Hz, 1H), 4.13 (q, J = 7.04 Hz, 2H), 3.87 (m, 1H), 
3.74 (dt, J = 7.0, 9.4 Hz, 1H), 3.50 (m, 1H), 3.38 (dt, J = 6.7, 9.5 Hz, 1H), 2.41 (m, 1H), 1.16-1.90 
(m, 37H), 1.14 (d, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ: 177.1, 98.9, 67.8, 63.2, 62.4, 60.1, 39.6, 33.9, 30.8, 29.7, 29.6, 
27.3, 26.3, 25.8, 25.6, 19.8, 17.2, 14.3. 
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2-Methyl-18-(tetrahydro-pyran-2-yloxy)-heptadecanoic acid (14) 
 
 
O
14
OHO
O
14
 
 
To a stirred solution of 13 (0.050 g, 0.117 mmole) in EtOH (0.35 mL) and H2O (0.35 mL), KOH ( 
0.32 g, 0.58 mmole) was added, the mixture was refluxed for 5 h. The mixture was allowed to cool 
to rt, then EtOH was evaporated under vacuum. The residue was acidified (pH =2) by 2N HCl and 
extracted with diethyl ether; the combined organic layers were dried over Na2SO4, filtered, and 
concentrated to obtain 14 as a colourless oil (0.035 g, 70 %) as an oil. Rf = 0.3 (EtOAc / hexane 
10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.57 (m, 1H), 3.86 (m, 1H), 3.72 (m, 1H), 3.49 (m, 1H), 2.45 (m, 
1H), 1.19-1.90 (m, 34H), 1.16 (d, J = 7.3 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ: 182.3, 98.9, 67.8, 63.2, 62.4, 39.3, 33.6, 30.8, 29.7, 27.2, 26.3, 
25.8, 25.5, 19.7, 16.9 
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2-Methyl-18-(tetrahydro-pyran-2-yloxy)-octadecanoic acid 1,2-dimethyl-5-oxo-2,5-dihydro-
1H-pyrrol-3-yl ester(16) 
 
 
 
 
A stirred solution of 6 (0.050 g, 0.39 mmole) in dry DCM (3 mL) at 0 oC was treated with DMAP 
(0.010 g, 0.08 mmol), 14 (0.156 g, 0.39 mmole) and finally with DCC (0.097 g, 0.47 mmole). 
Stirring was continued for 10 min at 0 oC and for another 5 h at rt . The mixture was filtered through 
a short plug of celite to remove most of the by-product urea; the filtrate was concentrated on a 
rotary evaporator and the remainder was purified by chromatography on silica gel, obtained 16 
(0.070 g, 35 %) as a white solid, Rf = 0.2 (EtOAc / hexane 50:50). 
 
1H NMR (300 MHz, CDCl3) δ: 6.02 (m, 1H), 4.57 (m, 1H), 4.04 (q, J = 7.0 Hz, 1H), 3.87 (m,1H), 
3.73 (m, 1H), 3.49 (m, 1H), 3.38 (m, 1H), 2.93 (s, 3H), 2.62 (m, 1H), 0.98-2.06 (m, 39H). 
13C NMR (75 MHz, CDCl3) δ: 177.1, 98.9, 67.8, 63.2, 62.4, 60.1, 39.6, 33.9, 30.8, 29.7, 29.6, 27.3, 
26.3, 25.8, 25.6, 19.8, 17.2, 14.3. 
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Octadecan-1-ol (24) 
 
OH
15
24
 
 
To a stirred solution of 23 (0.500 g, 1.6 mmol) in diethyl ether (15 mL) 2M LAH in THF (1.85 ml, 
2.2 eq, 3.7 mmol) was added at -10 oC. The reaction mixture was stirred for 1 h at 0 oC. The 
reaction was quenched with H2O at 0 oC.  The aqueous phase was extracted with diethyl ether (3 x 
20 mL). The combined organic layers were dried (Na2SO4), filtred and concentrated. Purification by 
flash column chromatography afforded 24 as a floppy white solid (0.41 g, 90 %). Rf = 0.3 (EtOAc / 
hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 3.64 (t, J = 7.3 Hz, 2H), 1.15-1.62 (m, 32H), 0.88 (t, J = 7.1 Hz, 
3H). 
 
 
 
 
 
 
 
 
 
 
  
128 
Octadecanal (25) 
 
 
 
 
To a stirred solution of 24 (0.410 g, 1.5 mmol) in DMC (15 mL) PCC (0.42 g, 1.9 mmol) was added 
and mixture was stirred for overnight at rt. Dilute the mixture with diethyl ether (20 mL), decant 
upper layer. Residue was washed with diethyl ether, combined organic layers filtered, and 
concentrated, Purification by flash column chromatography afforded 25 as a floppy white solid 
(0.35 g, 88 %). Rf = 0.7 (EtOAc / hexane 10:90). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H
O
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15
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3-Hydroxy-eicosanoic acid ethyl ester (26) 
 
OH
O
O
2615
 
 
 
A suspension of activated zinc dust (0.22 g, 3.3mmole) in 1 mL benzene was heated up to reflux for 
10 min. To the refluxing suspension was added ethyl bromoacetate (0.28 g, 1.6 mmole). After 5 min 
was added aldehyde 25 (0.300 g, dissolved in 2 ml benzene, 1.1 mmole) and after 2 h the refluxing 
mixture was cooled to rt then 1N HCl (2 mL) was added. The aqueous mixture was extracted with 
diethyl ether (3 x 10 mL). The combined organic layers were dried over Na2SO4, filtred, and 
concentrated. Purification by flash column chromatography afforded 26 as a white solid (0.35 g, 
88%). Rf = 0.25 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.2 (q, J = 7.2 Hz, 2H), 3.99 (m, 1H), 2.32-2.55 (m, 2H), 0.98-1.70 
(m, 32H), 0.87 (t, J = 7.2 Hz, 6H) 
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3-Oxo-eicosanoic acid ethyl ester (27) 
 
 
 
 
To a stirred solution of 26 (0.140 g, 0.39 mmol) in DMC (10 mL) PCC (0.110 g, 0.51mmol) was 
added and mixture stirred for overnight at rt. Dilute the mixture with diethyl ether (20 mL), decant 
upper layer. Residue was washed with diethyl ether, combined organic layers filtered, and 
concentrated. Purification by flash column chromatography afforded 27 as a white solid (0.100 g, 
72%). Rf = 0.73 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.19 (q, J = 7.3 Hz, 2H), 3.42 (s, 2H), 2.52 (t, J = 7.2 Hz, 2H), 1.52-
1.64 (m, 4H), 0.80-1.35 (m, 32H). 
 
 
 
 
 
 
 
 
 
 
 
 
O
O
O
27
15
  
131 
3-Hydroxy-eicosanoic acid (31) 
 
OH
OH
O
15
31
 
 
To a stirred solution of ester 26 (0.080 g, 0.22 mmole) in EtOH (1 ml) and H2O (1 mL) KOH (0.063 
g, 0.11 mmole) was added, the resulting mixture was stirred at rt for overnight. Ethanol was 
evaporated under vacuum and the aqueous mixture was acidified with 1N HCl and extracted with 
diethyl ether (2 x 10 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated, under vacuum to afford 31 as a white solid (0.060 g, 82 %). Rf = 0.18 (EtOAc / 
hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.03 (m, 1H), 2.39-2.63 (m, 2H), 1.10-1.60 (m, 32H), 0.88 (t, J = 
7.2 Hz, 3H). 
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2-[(3-Hydroxy-eicosanoyl)-methyl-amino]-propionic acid tert-butyl ester (32) 
 
OH
N
O
O
O15
32
 
To a stirred solution of acid 31 (0.100 g, 0.35 mmole), HCl salt of N-methyl L-alanine t-butyl ester 
(0.089 g, 0.45 mmole) in DCM (5 mL) TEA (0.061 g, 0.61 mmole), HOBT (045 g, 0.33 mmol) 
followed by DCC (0.069 g, 0.33 mmole) was added at 0 oC. The  resulting mixture was stirred  for 
1 h at 0 oC and then at rt overnight. The mixture was filtered through a short plug of celite to 
remove most of the by-product urea, the filtrate was concentrated on a rotary evaporator and the 
remainder was purified by chromatography on silica gel. Obtained 32 as a white solid (0.109 g, 70 
%), Rf = 0.6 (EtOAc / hexane 50:50). 
 
 
1H NMR (300 MHz, CDCl3) δ: 5.12 (m, 1H), 3.92-4.2 (m, 2H), 2.91 (s, 3H), 2.23-2.56 (m, 2H), 
1.0-1.71 (m, 44H), 0.87 (t, J = 6.6 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ: 173.3, 170.8, 81.6, 68.2, 56.2 52.6, 39.9, 36.4, 31.9, 31.4, 29.6, 
29.3, 28.0, 25.6, 22.6, 15.2, 14.5, 14.1. 
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2-tert-Butoxycarbonylamino-propionic acid  
HN
OH
O
Boc-DL-Ala
O
O
 
 
 
DL-Alanine (0.5 g, 5.6 mmole) was dissolved in dioxane-H2O (10 + 5 mL), the mixture was cooled 
to 0 oC and pH was adjusted to 8 by addition of 1N NaOH followed by di-tert-butyldicarbonate 
(1.34 g, 6.1 mmole) dropwise. The mixture was stirred at rt for 5 h , dioxane was evaporated under 
vaccum. The oily residue was cooled to 0 oC and acidified with 10 % HCl. The aqueous mixture 
was extracted with EtOAc (3 x 20 ml). The combined organic layers were dried (Na2SO4), filtered, 
and concentrated. Purification by flash column chromatography afforded Boc-DL-Alanine as a oil 
(0.900 g, 85 %).  
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2-tert-Butoxycarbonylamino-propionic acid 4-nitro-phenyl ester (35) 
 
 
 
 
HN
O
O
NO2
35
O
O
 
 
To a stirred solution of Boc-DL-Alanine (0.100 g, 0.52mmole) in DCM (5 mL) 4-Nitro phenol 
(0.88 g, 0.62 mmole) and EDCI (0.21g, 0.62mmole) were added at rt. The resulting mixture was 
stirred at rt overnight, crude product was purified by column chromatography to obtain 35 (0.120 g, 
73 %) as a yellow oil. 
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3-tert-Butoxycarbonylamino-3-hydroxy-2-propionyl-acrylic acid ethyl ester (36) 
 
 
 
 
O
O
O
NHHO
36
OO
 
 
 
 
The active methylene compound ethyl aceto acetate (0.050 g, 0.38 mmole) was added dropwise to a 
mixture of sodium hydride (60 % in oil, 0.34 mmole) in anhydrous benzene (0.5 mL) and the thick 
slurry thus formed was stirred at rt for 1 h. Compound 35 (0.094 g, 0.3 mmole) was then added to 
the mixture and stirring continued at 10 oC for 3 h. Water was added to the reaction mixture and the 
aqueous layer was separated and acidified with 10 % HCl, in an ice water bath and extracted with 
chloroform. The combined organic layers were dried (Na2SO4), filtered, and concentrated. 
Purification by flash column chromatography gave 36 (0.020 g, 18 %). Rf = 0.27(EtOAc / hexane 
30:70). 
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3-Acetyl-4-hydroxy-5-methyl-1,5-dihydro-pyrrol-2-one (37) 
 
 
 
 
NH
HO
OO
37
 
 
 
 
To a solution of NaOEt [prepared from Na (0.0018 g, 2.5.eq) in absolute ethanol (0.4 mL)] 36 
(0.010 g, 0.03 mole) in benzene (0.4 mL) was added at rt. Then reaction mixture was refluxed for 3 
h, ethanol was evaporated under vacuum, in remaining residue H2O was added 2 mL, and acidified 
with 10 % HCl in an ice bath. Then aqueous mixture was extracted with chloroform. combined 
organic layers were dried (Na2SO4), filtered, and concentrated, obtained 37 (0.009 g, 18 %). Rf = 
0.22 (MeOH / DCM 10:90),  
m/z = 154. 
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2-Methyl-17-(tetrahydro-pyran-2-yloxy)-heptadecan-1-ol (21)  
 
 
O
14
OHO
21
 
 
 
To a stirred solution of 13 (0.360 g, 0.84 mmole) in diethyl ether (13 mL) 2M LAH in THF (0.843 
ml, 2 eq, 1.6 mmol) was added at -10 oC. The reaction mixture was stirred for 1 h at 0 oC. Reaction 
was quenched with H2O at 0 oC, aqueous phase was extracted with diethyl ether (3 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash 
column chromatography afforded 21 as a floppy white solid (0.280 g, 95 %). Rf = 0.3 (EtOAc/ 
hexane 10:90). 
 
 
1H NMR (300 MHz, CDCl3) δ: 4.58 (t, J = 4.0 Hz, 1H), 3.87 (m, 1H), 3.72 (dt, J = 9.2, 7.7 Hz, 1H), 
3.32-3.55 (m, 4H), 1.0-1.92 (m, 38H), 0.91 (d, J = 6.75 Hz, 3H). 
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2-Methyl-17-(tetrahydro-pyran-2-yloxy)-heptadecanal (22) 
 
 
22
O
14
OH
O
 
 
 
 
To a stirred solution of 21 (0.280 g, 0.72 mmol) in DMC (10 mL) PCC (0.203 g, 0.94 mmol) was 
added and mixture was stirred for overnight at rt. Dilute the mixture with diethyl ether (20 mL), 
decant upper layer. Residue was washed with diethyl ether, combined organic layers filtered, and 
concentrated. Purification by flash column chromatography afforded 22 as a floppy white solid 
(0.225 g, 73 %). Rf = 0.6 (EtOAc / hexane 10:90). 
 
 
1H NMR (300 MHz, CDCl3) δ: 9.60 (d, J = 2.1 Hz, 1H), 4.57 (t, J = 4.4 Hz, 1H), 3.85 (m, 1H), 3.73 
(dt, J = 9.5, 6.9 Hz, 1H), 3.49 (m, 1H), 3.38 (dt, J = 9.5, 6.7 Hz, 1H), 2.29 (m, 1H), 1.15-1.80 (m, 
36H), 1.08 (d, J = 7.0 Hz, 3H) 
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3-Hydroxy-4-methyl-19-(tetrahydro-pyran-2-yloxy)-nonadecanoic acid ethyl ester (21) 
 
 
 
OH
O
O
THPO
15
21
 
 
 
A suspension of activated zinc dust (0.115 g, 1.7 mmole) in 1 mL benzene was heated up to reflux 
for 10 min. To the refluxing suspension was added ethyl bormo acetate (0.147 g, 0.88 mmole); after 
5 min was added aldehyde 22 (0.225 g, dissolved in 2 mL benzene, 0.58 mmole). After 2 h of 
refluxing the mixture was cooled to rt then 1N HCl (2 mL) was added; the aqueous phase was 
extracted with diethyl ether (3 x 10 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated. Purification by flash column chromatography afforded 21 as a white 
solid (0.216 g, 80%). Rf = 0.27 (EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.57 (t, J = 4.0 Hz, 1H), 4.17 (q, J = 7.3 Hz, 2H), 3.66-3.98 (m, 
3H), 3.50 (m, 1H), 3.37 (m, 1H), 2.44 (m, 2H), 1.03-1.41 (m, 39H), 0.90 (t, J = 7.3 Hz, 3H) 
13C NMR (75 MHz, CDCl3): δ: 173.4, 98.7, 71.7, 71.1, 67.6, 67.3, 62.2, 60.6, 46.4, 42.0, 38.7, 
38.0, 37.9, 37.7, 32.6, 32.2, 30.7, 29.8, 29.6, 27.2, 27.0, 26.1. 
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4-Methyl-3-oxo-19-(tetrahydro-pyran-2-yloxy)-nonadecanoic acid ethyl ester (20) 
 
 
O
O
O
THPO
15
20
 
 
 
 
To a stirred solution of 21 (0.216 g, 0.45 mmol) in DMC (10 mL) PCC (0.128 g, 0.59 mmol) was 
added and mixture was stirred for overnight at rt. Dilute the mixture with diethyl ether (20 mL), 
decant upper layer. Residue was washed with diethyl ether, combined organic layers filtered, and 
concentrated. Purification by flash column chromatography afforded 20 as a white solid (0.130 g, 
82 %). Rf = 0.73 (EtOAc / hexane 10:90). 
 
 
1H NMR (300 MHz, CDCl3) δ: 4.55 (t, J = 4.0 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.84 (m, 1H), 3.70 
(m, 1H), 3.44 (s, 2H), 3.29-3.52 (m, 2H), 2.59 (m, 1H), 0.75-1.87 (m, 42H). 
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2-(tert-Butoxycarbonyl-methyl-amino)-propionic acid 4-nitro-phenyl ester (38) 
 
 
N
O
O
38
NO2
O
O
 
 
 
 
To a stirred solution of Boc-N-Me-L-Alanine (0.215 g, 1.05 mmole) in DCM (5 mL) 4-Nitro phenol 
(0.146 g, 1.0 mmole) and EDCI (0.242 g, 1.2 mmole) was added at rt, resulting mixture was stirred 
at rt for overnight, crude product was purified by column chromatography obtained 38 (0.135 g, 40 
%) as a yellow oil. 
 
1H NMR (300 MHz, CDCl3) δ: 8.27 (m, 2H), 7.29 (2H, m), 4.77 (m,1H), 2.95 (s, 3H), 1.55 (d, J = 
7.3 Hz, 3H), 1.47 (s, 9H). 
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4-(tert-Butoxycarbonyl-methyl-amino)-3-hydroxy-2-[2-methyl-17-(tetrahydro-pyran-2-yloxy)-
heptadecanoyl]-pent-2-enoic acid ethyl ester (39) 
 
 
 
O
O
O
THPO
15
39
HO N BOC
 
 
 
 
The active methylene compound 20 (0.050 g, 0.14 mmole) was added dropwise to a mixture of 
sodium hydride (60 % in oil, 0.08 mmole) in anhydrous benzene (0.5 mL) and the thick slurry thus 
formed was stirred at rt for 1 h. Compound 35 (0.094 g, 0.3 mmole) was then added to the mixture 
and stirring continued at 10 oC for 3 h. Water was added to the reaction mixture and the aqueous 
layer was separated and acidified with 10 % HCl in an ice water bath and extracted with chloroform 
The combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash 
column chromatography afforded 39 (0.015 g, 16 %). Rf = 0.27(EtOAc / hexane 10:90). 
 
1H NMR (300 MHz, CDCl3) δ: 4.57 (m, 1H), 4.02-4.44 (m, 3H), 3.87 (m, 1H), 3.72 (m, 1H), 3.47 
(m, 1H), 3.38 (m, 1H), 2.52-2.92 (m, 4H), 0.73-1.93 (m, 54H). 
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CHAPTER 5 
 
 
Harzianic Acid 
 
 
5.1 Introduction 
In 1994 Sawa et al.1 isolated Harzianic acid, a new antimicrobial antibiotic from a Trichoderma 
harzianum strain, and attributed the structure (1a), except for the stereochemistry, on the basis of 
NMR studies. Later,  Kawasa et al.2 reisolated harzianic acid from a fungal strain (F-1531) endowed 
with inhibiting activity toward serine/threonine phosphatase type 2A (PP2A), together with the 
analogs demethylharzianic acid (1b) and homoharzianic acid (1c). Vinale et al.3 again obtained 
harzianic acid from a strain of Trichoderma harzianum, and established its absolute configuration as 
5’S,7’S by X-ray diffraction studies, and found that the compound has antifungal as well as plant 
growth promoting activity.  
5'
7'
CH3
 1a
 1b
 1c
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5.2 Biological activity 
Harzianic acid showed antibiotic activity3 against Pythium irregulare, Sclerotinia sclerotiorum, and 
Rhizoctonia solani. A plant growth promotion effect is reported at low concentrations of 1a. Plate 
antifungal assays with 10 µg of 1a completely inhibited the growth of the phytopathogenic agents 
P. irregulare and Sclerotinia sclerotiorum. Moreover, 62 % and 51 % inhibition was registered 
using 1 µg of the Trichoderma metabolite against P. irregulare and S. sclerotiorum, respectively. 
Kawada et al.2 found that harzianic acid is also a PP2A inhibitor. 
The pursuit of compounds containing tetramic acid groups with therapeutic properties has been 
undertaken for several decades, although comparatively few studies have been devoted toward their 
potential as anti-infective agents. Harzianic acid and epicoccamide are two quite unusual natural 
products since they are composed of biosynthetically two distinct subunits: fatty acid and tetramic 
acid. As we were synthesizing epicoccamide, we decided to develop a synthetic strategy for the 
preparation of  harzianic acid,  as both these natural compounds contain the tetramic acid moiety. 
 
5.3 Synthesis of Harzianic Acid 
Compound 1a has an intriguing structure, which includes a tetramic acid4 group in its N-
methylserine-derived heterocycle. Numerous biologically active natural products contain the 
tetramic acid (pyrrolidine-2,4-dione) ring system as a central element of their structure. The range 
of biological activities possessed by individual members of this series includes potent antibiotic, 
antiviral and antiulcerative properties, cytotoxicity and mycotoxicity, the inhibition of tumors as 
well as fungicidal action. Moreover, certain members of this class are responsible for pigmentation 
of some sponges and molds.4 The structural complexity, together with the potent biological activity, 
of many tetramic acids makes the total synthesis of these compounds an attractive goal for organic 
chemists. In addition, and differently from other members of the series, harzianic acid comprises a 
substituted skeleton bearing two stereogenic centers including one which is quaternary, whose 
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absolute configuration is 5’S,7’S. Other features are the conjugated double bond (E, E) and the side 
chain with the quaternary carbon center bearing –OH and -COOH functional groups. Harzianic acid 
has significant antifungal and plant growth promotion effect, which makes it a potential lead for the 
design of new antifungals.  
Herein, we describe the efforts towards the first total synthesis of harzianic acid (1a). 
 
5.3.1 Retrosynthesis 
Our retrosynthetic analysis is based upon the construction of the acyl tetramic nucleus. The tetramic 
acid subunit could be easily obtained by manipulation of an aspartic acid derivative in a Lacey–
Dieckmann cyclization.5 Our first strategy for the synthesis of 1a is based on the coupling of two 
domains: a side chain subunit 2 containing the quaternary stereogenic center, and a diene containing 
subunit 3; subunit 3 would require a Horner-Wadsworth–Emmons (HWE) reaction of the known 
phosphonate 156 with the commercially available aldehyde trans-2-hexen-1-al (Scheme 5.1). 
For construction of subunit 2, we found in literature Seebach’s report of the enantiospecific 
alkylation of several 1,3-dioxolanones prepared from α-hydroxycarboxylic acids and pivalaldehyde 
through the Li-enolate.7 This reaction has been applied to many total syntheses.8 Herein, we 
planned to employ the same strategy in our following approach. 
Harzianic acid contains two asymmetric centers at C5’ and C7’. The C5’ centre has an α - 
proton which is easily epimerized under basic conditions. Therefore, we planned to use a Garner 
aldehyde 9 which is commercially available. Considering the above fact, the retrosynthesis approach 
is depicted in scheme 5.1. The disconnections identified fragment 2, which can be constructed by 
treatment of dioxolanone 410 with commercially available (R)-Garner aldehyde.9 The dioxolanone 4 
can be prepared in a stereocontrolled fashion using commercially available L-valine.  
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Scheme 5.1 
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5.3.2 Synthesis of Subunit 3 
Subunit 3 had to be prepared in order to assemble the tetramic acid nucleus via Lackey-Dieckmann 
cyclisation. So we began the synthesis from commercially available 2,2,6-trimethyl-1,3-dioxen-4-
one and prepared known phosphonate 15 using a literature procedure.6 Horner–Emmons reaction of 
phosphonate 15 with commercially available trans-2 hexen-1-al using LDA afforded olefin 3 
(E/Z=9:1) in 43 % yield. We observed that the use of LiHMDS in this Horner-Emmons reaction 
does not improve the yield of olefin 3. (Scheme 5.2) 
 
Scheme 5.2. Synthesis of Subunit 3 
O O
O
O O
OCl
O O
OP
EtO
OEtO
O O
O
a b
c
14
15
3
 
Reagents and conditions : 
a) C2Cl6, LDA, THF; b) HP(O)(OEt)2, LDA, THF, -78 oC; c) trans-2-Hexen-1-al, LDA, -78 oC, 
THF, 3.5 h,43 %. 
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5.3.3 Synthesis of (2S,5S)-2-(tert-Butyl)-5-isopropyl-1,3- dioxolan-4-one (4) 
(S)-2-hydroxyisovaleric acid was commercially available only in small laboratory quantities and its 
relatively high cost raised a barrier to scale up synthesis. Instead, L-(+) valine was converted to (S)-
2-hydroxyisovaleric acid in 56 % yield.11 The acid-catalyzed condensation of (S)-2-
hydroxyisovaleric acid with pivalaldehyde in hexanes produced the crude dioxolane (4) as a 
mixture of cis/trans isomers in a 23:1 ratio. Attempts to remove the undesired trans isomer by a 
short-path distillation produced a less desirable 5:1 cis/trans mixture. It was then found that the 
crude dioxolane 4 could be purified by crystallization from an ether/pentane or hexanes solution to 
provide exclusively the cis isomer. (Scheme 5.3) 
 
Scheme 5.3. Synthesis of (2S,5S)-2-(tert-Butyl)-5-isopropyl-1,3- dioxolan-4-one 
 
OH
O
H2N
H
OH
O
HO
H
O O
O
H
H
L-Valine, S 2-Hydroxyisovaleric 
            acid
4
a b
(5S, 2S)
 
Reagents and conditions : 
a)NaNO2, H2SO4, H2O, rt, overnight, 56 %; b) Pivalaldehyde, hexane, p-TsOH, 82 %. 
 
Now both the dioxolane 4 and (R)-Garner aldehyde were in our hands. So we tried a steroselective 
alkylation; the reaction between (R)-Garner aldehyde and enolate of compound 4 was carried out by 
using the base LDA and THF at -78 oC for 2 h. After column chromatography purification the 
condensation product 5 was obtained in 50 % yield, and spectroscopic data including 1H-NMR and 
13C-NMR confirmed the structure. This molecule possesses a β-hydroxy group which was removed 
by Barton dexoygenation12,13 to provide the deoxygenated product 6 in 70 % yield with good 
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diasteroeoselectivity as determined by 1H-NMR spectroscopy. Selective deprotection of 6 with 
PPTS in refluxing ethanol14 for 1 h afford the Boc-protected β-aminoalcohol 7 in 50 % yield. The 
primary alcohol 7 was oxidized to carboxylic acid 8 with PDC in DMF without  epimerization at 
the C4 position14. Esterification of acid 8 carried out by using MeI, K2CO3 in DMF afford the ethyl 
ester 9 in good yield. In order to get subunit 2 we decided to carry out the N-methylation of 9 by 
very mild reaction conditions, and therefore we used MeI and Ag2O in DMF at 50 oC. 
Unfortunately, we were not able to obtain 10, as the cyclised compound 13 was formed, as 
confirmed by 1H-NMR. We tried this reaction in different reaction conditions but we were unable to 
obtain the desired compound 10. After all these attempts we concluded that the methylation of 
intermediate 9 is difficult as the intermediate 9 prefers cyclisation. If we could have obtained 
intermediate 10 it could have been converted to intermediate 2 by treating with 0.1N HCl/HCO2H, 
or selective deprotection of the Boc of intermediate 10 by AlCl3 in DCM should have given 
compound 12. 
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Scheme 5.4. Synthesis of intermediate 2 
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Reagents and conditions : 
a) LDA, THF, -78 oC, 2 h, 50 %; b) NaH, CS2, n-Bu3SnH, AIBN, toluene, reflux, 2 h, 70 %; c) 
PPTS, EtOH/H2O (95:5), reflux, 1 h. 50 %; d) PDC, DMF, rt, 48 h, 72 %. e) K2CO3, MeI, DMF, rt, 
overnight; f) Ag2O, MeI, DMF, 50 oC, 12 h; g) 0.1N HCl/HCO2H, reflux, 30 min. h) AlCl3, DCM, 
rt. 
 
Scheme.5.4.1 
O O
O
3
HO OH
O
HN
EtOOC
2
2S, 4S
OH
O N
COOEt
HOOC
HO
N
HO
OHO
O
O
HO
1
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b
Reagents and conditions : 
a) Toluene, reflux; b) KtOBu, tBuOH. 
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5.4.Future perspectives 
Once subunit 2 and 3 were in our hand they could be coupled by a Lacey-Dieckmann cyclisation in 
refluxing toluene, to complete the total synthesis of Harzianic acid 1a (Scheme 5.4.1) As we were 
unable to obtain the intermediate 2, we decided not to carry this synthetic pathway. In order to 
complete the synthesis of harzianic acid one should protect the side chain subunit 2 containing 
carboxylic acid, and hydroxyl group and these protection must not interact with nitrogen by 
intermolecular reaction that leads to cyclisation. So, looking for another synthetic approach toward 
the synthesis of harzianic acid, we found in literature that the side chain subunit 2 could be 
constructed by the procedure mentioned by Moldavi.15 The author protected the acid as ethyl ester 
and hydroxyl group as a benzyl ether starting from commercial available isopropylmalonic ester. 
Considering the above facts we revised the retrosynthesis again as depicted in scheme 5.5. 
The disconnection identified the known fragments subunit 2 and subunit 3. The fragment subunit 2 
could be constructed by coupling of intermediate 17 and protected glycine, whereas intermediate 17 
could be obtained from commercially available isopropylmalonic ester by partial modification of a 
literature procedure.15 
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Scheme 5.5 
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Considering this new retrosynthetic approach, we designed a new synthetic pathway for total 
synthesis of harzanic acid as a future perspective. Isopropylmalonic ester can be oxidized by 
benzoylperoxide in presence of Na2S2O3 or NaHSO3 to obtain 17 and the hydroxyl group must be 
protected as the benzyl ether 18 using benzyl chloride. Further partial hydrolysis of diester 18 could 
be achieved by literature procedure,15 to obtain 19. Finally, reduction of acid 19 followed by 
oxidation must give aldehyde 20 which must be reacted with the enolate of protected glycine16 to 
give condensed product 21. This molecule possesses a β-hydroxyl group which could be removed 
by Barton deoxygenation12,13 to provide deoxygenated product 22, and the diasteroeoselectivity can 
be determined by 1H-NMR spectroscopy. The following steps include Cbz deprotection by H2/Pd 
should give 23. Once the subunit 23 and 3 are in our hand they can be coupled by a Lacey-
Dieckmann cyclisation in refluxing toluene, to complete the total synthesis of Harzianic acid 1 
(Scheme 5.6) 
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5.5. Conclusion  
We have designed and synthesized the C8-C7’ fragment of harzianic acid. The evaluation of the 
biological activity of this intermediates and completion of total synthesis of harzianic acid  is in 
progress. 
5.6 Experimental section  
6-(chloromethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (14) 
 
 
O O
OCl
14
 
LDA (1.8M, 9.04 g, 54 mL) in 40 ml THF was cooled to -78oC and treated with dioxene (7.71 mL 
58.0 mmole) in THF (10 mL) over 20 min. During addition a fine yellow suspension formed. The 
enolate solution was stirred at -78 oC for an additional 15 min, then transferred to another flask 
containing hexachloroethane (20 g, 84.4 mmole) in THF (75 mL) at -50 oC to -55 oC over 30 min. 
When the addition was complete, the residual enolate was transferred with an additional portion of 
THF (10 mL). The resulting reaction mixture allowed to warm slowly at -25 oC over 30 min and 
poured into ice-cold aq 10 % HCl (100 mL) and the mixture was briefly shaken to discharge the red 
color. The organic layer was separated, and the aqueous layer extracted with ether (2 x 50 mL). The 
combined organic extracts were washed with saturated aqueous sodium bicarbonate solution (50 
mL), saturated aqueous sodium chloride (50 mL), dried over Na2SO4, concentrated. The crude 
product was purified by column chromatography to afford 14 (6.0 g, 60 %) 
 
Rf 0.57 (Ethyl acetate/hexane 2:8). 
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Diethyl (2,2-dimethyl-6-oxo-6H-1,3-dioxin-4-yl)methylphosphonate (15) 
 
O O
OP
EtO
OEtO
15
 
 
To a cold solution of tBuOK (11.43 g, 101.9 mmole) in DMF (100 mL) diethyl phosphate (14.59 g, 
105.0 mmole) was added dropwise. The resulting solution was stirred in an ice bath for 20- 40 min 
and then treated dropwise with a solution of 14 (6.0 g, 33.9 mmole) in THF (25 mL) over 20 min. 
The resulting purple solution was stirred for additional 15 min at 0 oC and treated with conc. HCl 
until the purple colour was discharged (approx 3 mL). The resulting mixture was filtered through 
celite bed, and the collected solid was washed with THF (2 mL). The combined organic portions 
were treated with several grams of anhydrous potassium carbonate, filtered and the THF was 
removed with a rotary evaporator. DMF and excess diethyl phosphate were removed by distillation. 
The residue was diluted with ethyl acetate (100 mL) and placed in the refrigerator at 0 oC overnight. 
The solid which precipitated was removed by filtration and the filtrate was concentrated under 
reduced pressure and purified by column chromatography to afford 15 (4.2 g, 50 %).  
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6-Hepta-1,3-dienyl-2,2-dimethyl-[1,3]dioxin-4-one (3) 
 
O O
O
 
 
To a solution of 4 (1.50 g, 3.59 mmol) in THF (30 mL) was added LDA (1.8 M in heptane, 2.3 ml, 
4.13 mmol) at 0 °C. After stirring for 30 min, the reaction mixture was cooled to –78 ºC. A solution 
of trans-hexen-1-al (0.528 g, 3.59 mmol) in THF (5 mL) was added slowly to the reaction mixture, 
and the resulting mixture was stirred at –78 ºC for 3.5 h. The reaction was quenched by adding 
saturated aqueous NH4Cl, extracted with ethyl acetate (3 x 40 mL).  The combined organic extracts 
were washed with brine, over anhydrous Na2SO4, filtered and concentrated. The residue was 
purified by flash column chromatography (Ethyl acetate/hexane 8:92) to afford olefin 3 (0.55 g, 43 
%) as a colorless oil. Rf 0.43 (Ethyl acetate/hexane 2:8). 
 
1H NMR (CDCl3) δ: 6.90 (dd, J = 10.71, J = 15.55, 1H), 6.00- 6.24 (m, 2H), 5.88 (d, J = 
5.27 Hz, 1H), 5.27 (s, 1H), 2.14 (m, 2H), 1.69 (s, 6H), 1.44 (m, 2H), 0.90 (t, J = 7.4 Hz, 
3H). 
13C NMR (CDCl3) δ: 163.8, 162.1, 143.8, 138.7, 129.1, 120. 9, 106.3, 94.0, 35.2, 25.1, 
22.7. 
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(S)-(+)-Hydroxyisovaleric Acid 
 
OH
O
HO
H
2-Hydroxyisovaleric 
            acid
 
 
To a suspension of L-valine (14.2 g, 121.2 mmol) in H2O (60 mL) conc. H2SO4 (3.41 mL, 63.00 
mmol) was added slowly, affording a clear solution. Ice (40 g) was added to the solution, cooling 
the reaction mixture to below 5 °C. Cooling was aided by the use of an external ice bath. A solution 
of sodium nitrite (10.6 g, 6.2 mol) in water (40 mL) was added slowly, while maintaining the 
reaction temperature below 5 °C. When the addition of sodium nitrite was complete, the stirred 
solution was allowed to warm to ambient temperature slowly, overnight. The pH of the reaction 
mixture was adjusted to 3-4 by the slow addition of solid sodium bicarbonate, and this solution was 
extracted with ethyl acetate (3 x 40 mL). The combined organic extracts were dried over anhydrous 
Na2SO4, filtered and concentrated. The residue was crystallized from ethyl acetate/hexanes (3:1) to 
afford (S)-(+)-Hydroxyisovaleric Acid (8 g, 56 %). 
 
1H NMR (CDCl3) δ: 4.16 (d, J = 3.5 Hz, 1H), 2.17 (m, 1H), 1.07 (d, J = 6.7 Hz, 3H), 
0.93 (d, J = 7.0 Hz, 3H). 
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(2S,5S)-2-(tert-Butyl)-5-isopropyl-1,3- dioxolan-4-one (4). 
O O
O
H
H
4 (5S, 2S)
 
 
To a solution of (S)-(+)-Hydroxyisovaleric acid (4 g, 33.8 mmol) in hexanes (32 mL) 
trimethylacetaldehyde (4.11 g, 47.0 mmol) and p-toluenesulfonic acid (0.041 g, 0.215 mmol) were 
added. The reaction mixture was heated under reflux until approximately 1.5 mL of water was 
collected. Heating was discontinued, and the colorless solution was allowed to cool to room 
temperature. The reaction mixture was poured into saturated aqueous NaHCO3 solution (400 mL), 
and the layers were mixed well. The layers were separated, and the aqueous layer was extracted 
with ethyl acetate (3 x 40 mL). The combined organics were dried (Na2SO4), filtered, and the 
solvent was removed in vacuo to afford a colorless oil which consisted of a 20:1 mixture of 
diastereomers, by NMR analysis. Crystallization from hexanes afforded 4 (5.16 g, 82 %) as white 
crystals. Rf 0.71 (Ethyl acetate/hexane 35:65). 
 
 
1H-NMR (CDCl3) δ: 5.09 (d, J =1.2 Hz, 1H), 4.09 (dd, J =3.7 Hz, 1H), 2.19 (m, 1H), 
1.11 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 7.1 Hz, 3H), 0.99 (s, 9H). 
 
 
 
 
 
  
165 
(R)-tert-butyl4-(((2S,4R)-2-tert-butyl-4-isopropyl-5-oxo-1,3-dioxolan-4yl)(hydroxy)methyl)-
2,2-dimethyloxazolidine-3-carboxylate (5) 
 
N
O
Boc
HO
O O
O
H
5
 
Dioxolanone 4 (0.5 g, 2.6 mmole) was dissolved in dry THF (12 mL) and cooled to -78 oC. LDA 
(1.8 M, 2.25 mL, 1.5 eq, 4.0 mmole) was added to above solution and reaction mixture stirred for 
10 min. (R)-Garner aldehyde (0.615 g, 2.6 mmole in 3 mL THF) was cooled at 0 oC and added to 
the above solution at -78 oC. Then the reaction mixture was stirred continuously for 3 h at -78 oC, 
TLC (20 % EtOAc in hexane) showed reaction progress. Then reaction was quenched with 10 mL 
aq NH4Cl and stirred for 1 h till rt. The organic mixture was extracted with Et2O (35 mL x 3) and 
the combined organic layer dried over Na2SO4, filtered and concentrated under vacuum. The 
residue was purified by flash column chromatography (12 % EtOAc – hexane) to afford 5 (0.45 g, 
45 %). Rf 0.49 (Ethyl acetate/hexane 2:8). 
 
1H-NMR (CDCl3) δ: 5.07 (s, 1H), 4.44 (m, 2H), 4.23(m, 1H), 3.90 (m, 1H), 2.64 (brs, 1H), 2.04 
(m, 1H), 1.32-1.66 (m, 15H), 0.96-1.1 (m, 15H). 
13C NMR (CDCl3) δ: 174.7, 172.5, 152.4, 110.8, 10.0, 94.2, 93.1, 88.3, 80.8, 70.1, 63.2, 62.8, 61.4, 
58.1, 57.4, 35.3, 34.7, 34.3, 33.7, 33.1, 31.6, 31.3, 28.56, 27.0, 26.4, 24.6, 24.0, 22.7, 18.9, 18.5, 
17.7, 16.3, 14.2 
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(S)-tert-butyl4-(((2S,4S)-2-tert-butyl-4-isopropyl-5-oxo-1,3-dioxolan-4-yl)methyl)-2,2 
dimethyloxazolidine-3-carboxylate (6) 
N
O
Boc O O
O
H
6
 
To a stirred solution of 5 (0.390 g, 0.93 mmole) at 0 oC in THF (10 mL) under N2 was added NaH 
(0.150 g, 4 eq). The stirred mixture was allowed to warm to rt over 30 min before CS2 (0.23 mL, 3.7 
mmole) was added. After 10 min, methyl iodide (0.23 mL, 3.7 mmole) was added and the solution 
became yellow. After another 10 min, the yellow color disappeared and the solution was cooled to 
0oC. Saturated aqueous NH4Cl (8 mL), diethyl ether (30 mL) and H2O (4 mL) were added. The 
separated aqueous phase was extracted with diethyl ether (15 mL x 2) and the combined organic 
phases were washed with saturated aqueous NaCl (10 mL), dried over Na2SO4, filtered, and 
concentrated. The residue was azeotropically dried from benzene (20 mL) and then dissolved in 
toluene (50 mL). After that the resultant solution was deoxygenated with a stream of N2 for 15 min, 
AIBN (0.616 g, 3.7 mmole) and Bu3SnH (1.98 ml, 2.18 g, 7.5 mmole) were added, and the mixture 
was heated at 80oC for 3 h under N2. After the solution was cooled to rt it was diluted with ethyl 
acetate (30 mL) , washed with H2O (10 mL) and saturated aq NaCl, dried over Na2SO4 and 
concentrated. The crude product purified by column chromatography (10 % EtOAc in Hexane) to 
afford 6 (0.216 g 70 %). 
Rf 0.5 (Ethyl acetate/hexane 2:8). 
1H-NMR (CDCl3) δ: 5.20 (s, 1H), 4.11 (m, 1H), 3.95(m, 2H), 2.25 (m, 1H), 2.10 (m, 2H), 1.50 (s, 
9H), 0.95-1.10 (m, 21H). 
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tert-butyl(S)-3-((2S,4S)-2-tert-butyl-4-isopropyl-5-oxo-1,3-dioxolan-4-yl)-1-hydroxypropan-2-
ylcarbamate (7) 
 
 
N
H
HO
Boc O O
O
H
7
 
To a stirred solution of 6 (0.287 g, 0.72 mmole) in ethanol : H2O (5 mL : 0.25 mL) and PPTS (0.23 
g, 0.92 mmole) were added and the resulting mixture heated to reflux for 3 h. TLC showed the 
completion of reaction, solvent was evaporated and EtOAc (40 mL) added and washed with H2O 
(10 mL). Organic layer dried on Na2SO4, filtered and concentrated to afford 7 (0.134g, 52 %) 
 
Rf 0.2 (Ethyl acetate/hexane 2:8) 
1H-NMR (CDCl3) δ: 5.35 (s, 1H), 4.78 (m, 1H), 4.00 (m, 1H), 3.52-3.70 (m, 2H), 2.10 (m, 2H), 
1.95 (m, 1H), 1.43 (s, 9H), 0.85-1.10 (m, 15H). 
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(S)-2-(tert-butoxycarbonyl)-3-((2S,4S)-2-tert-butyl-4-isopropyl-5-oxo-1,3-dioxolan-4-
yl)propanoic acid (8) 
O O
O
HNH
HOOC
Boc
8
 
To a stirred solution of 7 (0.134 g, 0.34 mmole) in DMF (6 mL) PDC (0.846 g, 2.2 mmole) was 
added and resulting reaction mixture stirred at rt for 48 h. Then EtOAc (30 mL) was added to 
reaction mixture and washed with 0.1N HCl. Then organic layer dreed over Na2SO4, filtered and 
concentrated to obtained crude 8 (0.130 g) which was used for next reaction without purification. 
 
Rf 0.3 (Ethyl acetate/hexane 4:6) 
 
1H-NMR (CDCl3) δ: 5.21 (s, 1H), 4.94 (m, 1H), 4.60 (m, 1H), 2.43 (m, 1H), 2.07 (m, 2H), 1.46 (s, 
9H), 0.80-1.18 (m, 15H). 
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(S)-methyl-2-(tert-butoxycarbonyl)-3-((2S,4S)-2-tert-butyl-4-isopropyl-5-oxo-1,3-dioxolan-4-
yl)propanoate (9) 
 
O O
O
HNH
H3COOC
Boc
9
 
To a solution of 8 (0.112 g, 0.3 mmole) in DMF (0.5 mL) cooled to 0 oC, K2CO3 (0.046 g, 0.31 
mmole) was added and the reaction mixture stirred for 10 min. MeI (0.037 mL, 0.6 mmole) was 
added drop wiseand the resulting reaction mixture stirred overnight.TLC showed completion of 
reaction, reaction mixture was filtered, washed with EtOAc and extracted with EtOAc (15 mL x 3), 
combined organic layer were washed with H2O, brine and then dried over Na2SO4, and purified by 
column chromatography, to afford 9 (0.070 g, 60 %) as a yellow oil. 
Rf 0.4 (Ethyl acetate/hexane 2:8) 
 
1H-NMR (CDCl3) δ: 5.23 (s, 1H), 4.86 (m, 1H), 4.58(m, 1H), 3.76 (s, 3H), 2.35 (m, 1H), 2.02 (m, 
2H), 1.43 (s, 9H), 1.07 (d, J = 6.4 Hz, 15H). 
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CHAPTER 6 
 
Synthesis of 3,7-Diaryl-1,4-dihydro[1,2,4]triazolo[5,1,-C][1,2,4]triazines 
6.1 Introduction 
The chemistry of heterocyclic compounds continuous to be an explored field in organic chemistry. 
Heterocyclic compounds have long played a dominant role in medicinal chemistry and in the 
science of crop protection.1 Heterocycles, their preparation, transformation, and properties, are 
undoubtedly a cornerstone of organic chemistry. Several books not only on heterocyclic chemistry3-
7
 but also on some special aspects, such as heterocyclic name reaction, heterocyclic palladium-
catalyzed reaction8, heterocyclic carbene complexes,9 and fluorinated heterocycles,10 have been 
published recently. Approximately more than 70 % of all pharmaceuticals and agrochemicals bear 
at least one heterocyclic ring. In addition, some of the biggest commercial products to date, such as 
the broad-spectrum fungicide azoxystrobin (Amistar),11 currently applied against disease of more 
than 100 different crops in more than 100 countries, belong to this huge heterocyclic group of active 
ingredients. There are two major reasons for the tremendous value of heterocycles for the lead 
optimization of pharmaceuticals and agrochemicals. The heterocyclic scaffold of a drug often has a 
positive impact on its synthetic accessibility and its physicochemical properties, driving the values 
of lipophilicity and solubility toward the optimal balanced range regarding uptake and 
bioavailability. Furthermore, heterocycles seem to be perfect bioisosteres of other iso- or 
heterocyclic rings as well as of several different functional groups, in most cases delivering through 
their similarity in structural shape and electronic distribution equal or even better biological 
efficacy.12 
Among all these heterocyclic compounds, triazole and triazine derivatives occupy a unique 
position in heterocyclic chemistry. Substituted triazoles have received considerable attention during 
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last two decades as they are endowed with a variety of biological activities and have wide range of 
therapeutic properties. A literature survey indicates that  triazole derivatives possess different 
pharmacological activity and agrochemical activity such as analgesic, antiasthmatic, 
antihypertensive, fungicide, herbicide, and insecticide.13-16 
] The fungicide group of demethylation inhibitors (DMI), which contains the triazole 
fungicides, was introduced in the mid-1970s. Triazoles consist of numerous members, of which 
several are labeled or are in the process of being labeled for use on field crops: cyproconazole, 
flusilazole, flutriafol, metconazole, myclobutanil, propiconazole, prothioconazole, tebuconazole, 
and tetraconazole (Fig 1). 
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Triazoles are used on many different types of plants including field crops, fruit trees, small fruit, 
vegetables, and turf. These fungicides are highly effective against many different fungal diseases, 
especially powdery mildews, rusts, and many leaf-spotting fungi.  
Over the past 50 years, triazines have made a great impact on agriculture and world hunger 
by assisting in the development of new farming methods, providing the greater farming and land 
use capabilities, and increasing crop yields. The initial discovery and development of triazine 
herbicides took place between year 1950 and 1970.  During this period, a group of leading scientist 
and agriculture experts of the former chemical company J. R Geigy, Ltd., developed an idea for a 
new family of herbicides that would support the modern agriculture. A small team of Geigy 
chemist, biologists and agronomists made excellent progress in turning that initial concept into not 
only new compounds, but a new field of weed control research. The discovery and development of 
triazine herbicides were important scientific achievements and a significant example of cooperation 
among chemists, biologists, and agronomists from around the world. Development of the triazines 
led to unprecedented success in crop weed management. 
Triazines are registered in over 80 countries and save billions of dollars a year. The triazine 
herbicides is the one book that presents a comprehensive view of the total science and agriculture of 
these chemicals. Triazines herbicides are commonly used weed killers in crop production lawns. 
They work by inhibiting the process of photosynthesis in weeds. They are absorbed by weed roots 
and translocated upward throughout the plant. Triazines are popular because they control a wide 
range of weeds. Both broad-leaf weeds and grasses are susceptible to herbicides of this chemical 
family. Most herbicides control either broad-leaf weeds or grasses but not both. The triazine family 
of herbicides, which includes atrazine, were introduced in the 1950s; they have the current 
distinction of being the herbicide family of greatest concern regarding groundwater contamination. 
Atrazine does not break down readily (within a few weeks) after being applied to soils of above 
neutral pH. Under alkaline soil conditions, atrazine may be carried into the soil profile as far as the 
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water lavel by soil water following rainfall causing the aforementioned contamination. Atrazine is 
thus said to have "carryover", a generally undesirable property for herbicides. Triazines consist of 
numerous members, of which several are labeled or are in the process of being labeled for use on 
field crops such as Ametryn, Cyanazine, Metribuzin, Bladex and Princep (Fig 2). 
Fig. 2. 
N
N
N
Cl
N
H
N
H
Atrazine
N N
N
NH
H
NS
Ametryn
N N
N
Cl
H
N
H
N
Cyanazine
N
N
N
O
NH2
S
Metribuzin
 
 
Both these heterocycles have unique value in agrochemical industry. As a part of our ongoing 
studies on compounds endowed with fungicidal activity, we became interested in investigating new 
heterocyclic scaffolds as structural analogues of natural nucleic bases. In particular we focused on 
1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazine (Fig. 3) as a core structure and we planned to 
develop a general method for the synthesis of this ring system that might be amenable to the 
preparation of 3,7-diaryl-substituted derivatives 1 of triazole-triazine fused ring system in order to 
find new fungicides and to study the structure-activity relationship. The triazole-triazine fused ring 
system occurs in the structures of many pharmaceutical and agrochemical active compounds and 
other commercial substance. A wide range of synthetic methods, therefore, have been developed for 
construction of such fused ring systems. 
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Recently some compounds containing triazolo-fused heterocyclic ring such as 1,2,4-
triazolo[5,1-c][1,2,4]triazin-7-one17 and 1,2,4-triazolo[1,5-a]pyrimidine,17,18 have shown potent 
antiviral activity. Triazolotriazine heterocycles are among the least known in the polyazaindolizine 
series19-23 and 3,7-diaryl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazines 1 have been even less 
studied. In particular triazolo[2,3-b]triazine 3 have never been described and only triazolo[4,3-
b]triazines 2. triazolo[3,4-c]triazines 4, and triazolo[3,2-c]triazines 5 substitued with phenyl, amino, 
hydroxyl, or mercapto group are known.19-24 The synthesis and properties of unsbustituted and 
methyl-substituted triazolo-triazine 2-5 were of interest in conjunction with previous investigations 
in the triazine20 and azaindolizine series25. 
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6.2 Reported Synthesis 
Indeed, to the best of our knowledge, only one method for the synthesis of this class of compounds 
has been described so far. Namely, Hatzheim and co-workers26-28 have reported a synthetic pathway 
from 2-amino-5-aryl-3-phenacyl-1,3,4-oxadiazolium bromides by ring transformation with 
hydrazine. Low yields and the requirement of multistep synthesis for each building block hamper 
the use of this approach as a general protocol for the preparation of 3,7-diaryl-1,4-
dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazines. In 1977 Daunis and Lopez19 reported a procedure to 
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obtain 3-methyl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazine 9 via reaction of 5-chloro-1H-1,2,4-
triazole 6 with chloroacetone. After chromatographic separation of the two isomeric 1-(3-chloro-
1H-1,2,4-triazol-1-yl)- and 1-(5-chloro-1H-1,2,4-triazol-1-yl)propan-2-ones, 8 and 7 respectively, 
the latter was treated with hydrazine to obtain the cyclized triazine in a 14 % overall yield (Fig. 3) 
Fig. 3 
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6.3 Retrosynthetic Approach 
Treating 5-chloro-1H-1,2,4-triazole with chloroacetone by Daunis and Lopez19 reported method 
gave a mixture of two regiosomers, due to unsymmetry of the molecule. We envisaged that this 
strategy could be implemented by alkylating 3,5-dibromo-1H-1,2,4-triazole instead of 5-chloro-1H-
1,2,4-triazole. The use of 3,5-dibromo-1H-1,2,4-triazole could give two main advantages. First, the 
symmetry of the molecule overcomes regiochemical difficulties, as alkylation should occur at N-1 
due to the higher nucleophilicity of the N–N system,29 giving only one product. This would avoid a 
troublesome separation of isomers. Second, the presence of a further bromine group would allow 
the subsequent elaboration of the template, by introducing differently substituted aromatic rings via 
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Suzuki coupling with various commercially available boronic acids. The retrosynthesis is outlined 
in Scheme 1. The disconnection identified the fragment 11 as a phenacylated 3,5-
dibromo[1,2,4]triazole which could be obtained by alkylation of commercially available 3,5-
dibromotriazole with phenacyl bromide. Alternatively, the bromine atom could be removed by 
catalytic hydrogenation to obtain the monoaryl derivatives 12. 
Scheme 1 
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6.4 Synthesis 
 
According to this strategy, 1H-1,2,4-triazole was brominated by using bromine with potassium 
bromide. The reaction was carried out at 110oC for 2 h in the presence of H2O as a solvent, the 
excess of bromine was removed by heating reaction mixture for another 15 min, and a solid 
precipitated out. This was filtered, washed with H2O and dried under high vacuum to afford an 88 
% yield of 3,5-dibromo-1H-1,2,4-triazole 13,30which matches with commercial available 13. 
Compound 13 was then alkylated with phenacyl bromide by using potassium carbonate as a base 
and acetone as a solvent, reaction carried out at rt for 4 h. (Scheme 1). As expected, alkylation 
occurred at N-1 and gave the 3,5-dibromo-1-phenacyltriazole 11 in 82 % yield. The product was 
fully characterized by 1H NMR and 13C NMR, whereas the alkylation at N-1 was confirmed by the 
presence of aromatic protons at δ 7-8 and of a methylene proton at δ 5.60 (2H, m). Treatment of 11 
with hydrazine hydrate in methanol at reflux temperature for 6 h produced an intermediate that 
spontaneously cyclized to give 7-bromo-3-phenyl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazine 
10 in 60 % yield. The spectroscopic data, including 1H-NMR, 13C-NMR and mass spectra 
confirmed the structure. Finally, reaction with 4-methoxyphenylboronic acid under Suzuki 
conditions afforded 14 in 60–70% yield. Alternatively, the bromine atom was easily removed from 
10 by catalytic hydrogenation in presence of methanol to obtain the monoaryl derivative 12 in 85% 
yield.31 Appearance of a new peak at δ 7.80 (1H) in 1H-NMR, and an additional peak at δ 146.3 in 
13C-NMR clearly indicated that debromination had occurred. We also investigated the possibility of 
introducing an alkyl fragment with a terminal hydroxy group on N-1, as this kind of chain seems to 
play a role in increasing the antiviral activity.17 Thus, treatment of compound 14 with 4-bromobutyl 
acetate in presence of aqueous sodium carbonate at rt for 2 h afforded 15 in 70 % yield. Analysis of 
1H-HMR, and 13C-NMR confirmed the structure, with the appearance of new peaks in the aliphatic 
region of 1H-HMR, and 13C-NMR. Further hydrolysis of ester 15 was carried out with sodium 
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methoxide in methanol17 at 70 oC for 0.5 h, to give after acidic workup compound 16 in 42 % yield 
over two steps as a white solid. (Scheme 2). 
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Reagents and conditions : 
a) Br2, KBr, KOH, H2O, reflux, 1.5 h, 60 %; b) PhCOCH2Br, K2CO3, acetone, rt, 4 h, 82 %; c) 
NH2NH2.H2O, MeOH,  reflux, 6 h, 60 %; d) 4-Methoxyphenylboronic acid, AcOH, PdCl2(PPh3)2, 
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DMF, H2O, 140 OC, 2 h, 60 – 70 %; e) Br(CH2)4OAc, Na2CO3, 100 oC, 2.5 h, 60 %; f) NaOMe, 
MeOH, reflux, 0.5 h, 70%.  
 
6.5 Synthesis of analogues  
 
  
 
Having the 3,7-diaryl-substituted derivatives 1 in our hands, the developed synthetic route allowed 
the preparation of a number of analogues which could be useful for determination of structure-
activity relationship (SAR).  
To determine the structure-activity relationship first we decided to replace bromine by 
differently substituted aromatic rings via Suzuki coupling with various commercially available 
boronic acids. We wanted to examine the role of different substituted aromatic rings in fungicidal 
activity. Accordingly, we chose five different aromatic boronic acids, namely, 3-
acetlyphenylboronic acid, 3-hydroxypheylboronic acid, 3-pyridineboronic acid, 4-
isopropoxyphenylboronic acid, and 4-trifluromehtylphenylboronic acid. We carried out Suzuki 
coupling between bromo intermediate 10 and boronic acids to obtain analogues 17, 18, 19, 20 and 
21 in 60-70 % yield (Scheme 4). We also synthesized the analogues of intermediate 10. We treated 
3,5-dibromo-1H-1,2,4-triazole 13, with two more acyl bromides, namely 2-bromo-4’-
nitroacetophenone and 2-chloro-4’-fluoroacetophenone by using potassium carbonate as base and 
acetone as solvent, reaction carried out at rt for 4 h to obtain intermediates 22 and 23 in 95-98 % 
yield. Treatment of these intermediate with hydrazine hydrate in methanol at reflux temperature for 
6 h produced an intermediate that spontaneously cyclized to give analogue 7-bromo-3-(4-
fluorophenyl)-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine 25 and 7-bromo-3-(4-nitrophenyl)-
1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine 24 (Scheme 3). 
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Scheme 3. 
N
N
NH
BrBr
N
N
N
Br
O
Br
N
N
N
N
H
NBr
13
NO2
N
N
N
Br
O
Br
F
N
N
N
N
H
NBr
NO2 F
22 23
24 25
a b
c c
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a) 2-Bromo-4’-nitroacetophenone, K2CO3, acetone, rt, 4 h, 98 %; b) 2-Chloro-4’-fluoroacetopheone, 
K2CO3, acetone, rt, 4 h, 98 %; c) NH2NH2.H2O, MeOH,  reflux, 6 h, 60-62 %. 
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Scheme 4. 
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6.6 Conclusion  
In conclusion, an expedient synthesis of 3,7-diaryl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazines 
in three steps from 3,5-dibromo-1H-1,2,4-triazole has been developed. The reactions were 
conducted under easy-to-perform, mild conditions with moderate to good yields. The synthesis 
affords easy entry to previously unreported heterocyclic compounds of potential pharmacological 
and agrochemical interest. 
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6.7 Experimental section 
3,5-Dbiromo-1H-[1,2,4]triazole (13) 
N
N
NH
BrBr
13
 
To a stirred solution of 1,2,4-triazole (1.38 g, 19.9 mmole) in 20 mL of H2O KOH (2.80 g, 49.9 
mmole, 2.5 eq) was added. This reaction mixture was heated to 80 oC for 10 min and then cooled to 
30 oC, Then Br2 (2.2 ml, 41.7 mmole, 2.1eq) in KBr-H2O (1.90 g, 2 mL) solution was added to 
above reaction mixture drop by drop at 30 oC. On refluxing for 1.5 h a solid precipitated, the 
reaction mixture was cooled and the white solid was filtered through a Buchner funnel, and 
thoroughly dried to give 13 (2.70 g, 60 %) as a white solid. 
m.p. = 215oC. 
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2-(3,5-Dibromo-[1,2,4]triazol-1-yl)-1-phenyl-ethanone (11):  
 
N
N
N
Br
O
Br
11
 
 
 
To the stirred solution of 13 (1.00 g, 4.40 mmole) and K2CO3 (0.61 g, 4.40 mmole) in acetone (10 
mL) was added phenacyl bromide (0.88 g, 4.40 mmole) at 0oC. Then reaction mixture was stirred 
for 4 h at rt. The reaction mixture was filtered, the residue washed with acetone.  The filtrate was 
concentrated under vacuum and the crude product crystallized form ethyl acetate and pet. ether, to 
obtain faint yellow solid 11 ( 1.23 g, 82 %).  
m.p. = 134oC, Rf = 0.33 (hexanes–EtOAc, 8:2). 
 
1H NMR (300 MHz, CDCl3): δ = 8.00–7.89 (m, 2H), 7.72–7.61 (m, 1H), 7.60–7.48 (m, 2H), 5.61 
(m, 2H). 
 
13C NMR (75 MHz, CDCl3): δ = 188.6, 140.5, 134.7, 133.6, 131.5, 129.2 (2 C), 128.1 (2 C), 55.4. 
Anal. Calcd for C10H7Br2N3O: C, 34.81; H, 2.05; N, 12.18. Found: C, 35.02; H, 2.33; N, 12.36. 
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7-Bromo-3-phenyl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazine (10) 
 
N
N
N
N
H
NBr
10
 
To a stirred solution of 11 (0.50 g, 1.4 mmol) in MeOH (7.5 mL), H2NNH2·H2O (0.265 g, 5.3 
mmol, 3.6 equiv) was added at r.t. The reaction mixture was refluxed for 6 h, then was cooled to r.t. 
The precipitated white solid was collected by filtration, washed with MeOH to remove side 
products and unreacted starting material, then dried to obtain 10 as a white shiny solid; yield 0.24 g 
(60 %); m.p. = 281°C, Rf = 0.46 (hexanes–EtOAc, 1:1). 
 
1H NMR (300 MHz, DMSO-d6): δ = 11.65 (s, 1H), 7.78–7.70 (m, 2H), 7.50–7.39 (m, 3H), 5.21 (s, 
2H). 
 
13C NMR (75 MHz, DMSO-d6): δ = 147.8, 138.3, 138.2, 134.4, 130.1, 129.0 (2 C), 125.4 (2 C), 
45.2. 
 
HRMS (ESI+): m/z [M + H]+ calcd for C10H9BrN5: 278.0035; found: 278.0036; m/z [M + Na]+ 
calcd for C10H8BrN5Na: 299.9855; found: 299.9856. 
Anal. Calcd for C10H8BrN5: C, 43.19; H, 2.90; N, 25.18. Found: C,43.36; H, 2.78; N, 25.22. 
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7-(4-Methoxyphenyl)-3-phenyl-1,4-dihydro[1,2,4]triazolo[5,1-c][1,2,4]triazine (14) 
 
N
N
N
N
H
N
O
14
 
To a stirred solution of the bromide 10 (0.05 g, 0.18 mmol) in DMF (1 mL), 4-methoxyphenyl 
boronic acid (0.032 g, 1.2 equiv) and K3PO4 (0.114 g, 3 equiv) were added under nitrogen, followed 
by H2O (0.5 mL). The reaction mixture was degassed with nitrogen for 15 min, then PdCl2(PPh3)2 
(0.006, 0.05 equiv) was added and the mixture was again degassed with nitrogen for 15 min. The 
reaction mixture was heated to 140 °C for 2 h, then was cooled to rt. and H2O (5 mL) was added. 
The aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated. The residue was purified by flash column chromatography 
(hexanes–EtOAc, 65:35); obtained 14 (0.037 g, 67 %). m.p. = 229–233 °C. 
Rf = 0.6 (hexanes–EtOAc, 1:1). 
 
 
1H NMR (300 MHz, DMSO-d6): δ = 11.53 (s, 1H), 7.88 (d, J = 8.8 Hz, 2H), 7.79–7.70 (m, 2H), 
7.49–7.39 (m, 3H), 7.00 (d, J = 8.8 Hz, 2H), 5.31 (s, 2H), 3.78 (s, 3H). 
 
13C NMR (75 MHz, DMSO-d6): δ = 160.4, 159.0, 147.3, 137.3, 134.8, 129.8, 129.0 (2 C), 127.6, 
127.3, 125.4, 125.2, 124.0, 114.5, 114.4, 55.6, 45.4. 
HRMS (ESI+): m/z [M + H]+ calcd for C17H16N5O: 306.1354; 
found: 306.1357; m/z [M + Na]+ calcd for C17H15N5NaO: 328.1174; 
found: 328.1172. 
 
Anal. Calcd for C17H15N5O: C, 66.87; H, 4.95; N, 22.94. Found: C, 67.06; H, 4.75; N, 22.78. 
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Acetic acid 4-[7-(4-methoxy-phenyl)-3-phenyl-4H-[1,2,4]triazolo[5,1-c]triazin-1-yl]butylester 
(15) 
N
N
N
N N
MeO
15
O O
 
A suspension of 7-(4-methoxy-phenyl)-3-1,4-dihydro-[1,2,4]triazolo[5,1-c]triazine (14, 0.050 g, 
0.16 mmol) in 17 % aqueous Na2CO3 (0.2 mL) was stirred at room temperature for 1.5 h; the 
precipitate was filtered off, dried and dissolved in DMF (1 mL). 4-Bromobutyl acetate (0.031 g, 
0.16 mmol) was added to the resulting solution and the reaction was heated for 2.5 h at 100 oC. The 
mixture was cooled, then water was added. The aqueous solution was extracted with ethyl acetate (3 
x 5 mL) and the combined organic layers were dried (Na2SO4), filtered and concentrated. The 
residue was purified by flash column chromatography (hexanes- EtOAc 8:2).to obtain 15 as a solid 
(0.042 g, 60 %), m.p. = 107-109 °C, Rf = 0.8 (hexanes- EtOAc 1:1).  
 
1H NMR (300 MHz, DMSO-d6) = 7.91 (d, J = 8.5 Hz, 2H), 7.85-7.75 (m, 2H), 7.50-7.40 (m, 3H), 
7.02 (d, J = 8.5 Hz, 2H), 5.34 (s, 2H), 4.07 (t, J = 6.4 Hz, 2H), 3.99 (t, J = 6.4 Hz, 2H), 3.80 (s, 3H), 
1.98 (s, 3H), 1.90-1.76 (m, 2H), 1.75-1.60 (m, 2H). 
 
13C NMR (75MHz, DMSO-d6) = 170.8, 160.5, 158.9, 147.9, 137.4, 134.4, 130.0, 129.0 (x 2), 
127.6 (x 2), 125.4 (x 2), 123.8, 114.6, 114.3, 63.8, 55.6, 51.0, 45.4, 25.3, 24.0, 21.0. 
Anal Calcd for C23H25N5O3: C. 65.85; H. 6.01; N. 16.70. Found: C. 65.98; H. 5.95; N. 16.82. 
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4-[7-(4-Methoxy-phenyl)-3-phenyl-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-1-yl]butan- 
1-ol (16) 
 
N
N
N
N
NMeO
OH
16
 
 
 
Acetic acid 4-[7-(4-methoxy-phenyl)-3-phenyl-4H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-1-yl]-butyl 
ester (15; 0.020 g, 0.05 mmol) was added to a solution of sodium methylate prepared from sodium 
(0.002 g, 0.09 mmol) and methanol (0.5 mL). The reaction mixture was refluxed for 0.5 h, cooled, 
neutralized with acetic acid and evaporated under vacuum. The products were isolated by column 
chromatography (EtOAc), to give 16 as a white solid (0.012 g, 70 %), m.p. = 127-130°C. 
Rf = 0.27 (hexanes-EtOAc 1:1). 
1H NMR (300 MHz, DMSO-d6) = 7.91 (d, J = 8.5 Hz, 2H), 7.83-7.73 (m, 2H), 7.53- 7.40 (m, 3H), 
7.02 (d, J = 8.5 Hz, 2H), 5.35 (s, 2H), 4.44 (t, J = 4.88 Hz, 1H), 4.01 (t, J = 6.7 Hz, 2H), 3.51-3.40 
(m, 2H), 3.90 (s, 3H), 1.98 (s, 3H), 1.89-1.74 (m, 2H), 1.57- 1.48 (m, 2H). 
 
13C NMR (75MHz, DMSO-d6) = 160.1, 158.5, 147.6, 136.8, 134.1, 129.6, 128.6 (x 2), 127.2 (x 2), 
125.0 (x2), 123.5, 114.1 (x2) 
 
Anal Calcd for C21H23N5O2: C. 66.83; H. 6.14; N. 18.55. Found: C. 66.53; H. 6.45; N. 18.74. 
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2-(3,5-Dibromo-1H-1,2,4-triazol-1-yl)-1-(4-nitrophenyl)ethanone (22) 
 
N
N
N
Br
O
Br
NO2
22
 
 
To the stirred solution of 13 (0.5 g, 2.20 mmole) and K2CO3 (0.304 g, 2.20 mmole ) in acetone (10 
mL) was added 2-bromo-4’-nitroacetophenone (0.537 g, 2.20 mmole) at 0 oC. Then reaction 
mixture was stirred for 4 h at r.t.. The reaction mixture  was filtered, the residue washed with 
acetone. The filtrate was concentrated under vacuum. The product was crystallized (EtOAc–
petroleum ether) to give 22 (1.681 g,98 %), as a yellow solid. 
 
m.p. = 148–153 °C, Rf = 0.26 (hexanes–EtOAc, 8:2). 
 
1H NMR (300 MHz, DMSO-d6): δ = 8.46–8.36 (m, 2H), 8.35–8.25 (m, 2H), 6.18 (s, 2H). 
 
13C NMR (75 MHz, DMSO-d6): δ = 190.6, 150.7, 139.5, 138.1, 132.8, 130.0 (2 C), 124.1 (2 C), 
56.5. 
 
Anal. Calcd for C10H6Br2N4O3: C, 30.80; H, 1.55; N, 14.37. Found: C, 31.02; H, 1.21; N, 14.60. 
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7-Bromo-3-(4-nitro-phenyl)-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine (24) 
 
N
N
N
N
H
NBr
NO2
24
 
 
 
To a stirred solution of 22 (1 g, 2.5 mmol) in MeOH (15 mL), H2NNH2·H2O (0.517 g, 9.2 mmol, 
3.6 equiv) was added at r.t. The reaction mixture was refluxed for 6 h, then was cooled to r.t. The 
precipitated white solid was collected by filtration, washed with MeOH to remove side products and 
unreacted starting material, then dried to obtain 24 as a white shiny solid (0.486 g, 60 %). 
m.p. = 291-295 oC, Rf = 0.43  
. 
1HMR (300 MHz, DMSO-d6) = 12.05 (brs, 1H), 8.31-8.21 (m, 2H), 8.01-7.90 (m, 2H), 5.30 (s, 
2H). 
 
13C NMR (75MHZ, DMSO-d6) = 147.6, 146.9, 140.1, 138.1, 136.1, 126.1 (x 2), 123.8 (x 2), 45.1. 
 
Anal Calcd for C10H7 BrN6O2: C. 37.17, H. 2.18, N. 26.01. Found: C. 37.39, H. 2.01, N. 26.26. 
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2-(3,5-Dibromo-1H-1,2,4-triazol-1-yl)-1-(4-fluorophenyl)ethanone (23) 
 
N
N
N
Br
O
Br
F
23
 
 
To the stirred solution of 13 (0.5 g, 2.20 mmole) and K2CO3 (0.304 g, 2.20 mmole ) in acetone (10 
mL) was added 2-Bromo-4’-fluoroacetophenone (0.380 g, 2.20 mmole) at 0 oC. Then reaction 
mixture was stirred for 4 h at rt. Reaction mixture  was filtered, residue washed with acetone, 
filtrate was concentrated under vacuum. The product was crystallized (EtOAc–petroleum ether) to 
give a yellow solid 23 (1.681 g, 98 %). 
m.p. = 154–159 °C, Rf = 0.36 (hexanes–EtOAc, 8:2). 
 
1H NMR (300 MHz, DMSO-d6): δ = 8.21–8.11 (m, 2H), 751–7.41 (m, 2H), 6.08 (s, 2H). 
 
13C NMR (75 MHz, DMSO-d6): δ = 189.8, 165.8, 139.4, 132.8, 131.6 (2 C), 130.4, 116.2 (2 C), 
56.1. 
 
Anal. Calcd for C10H6Br2FN3O: C, 33.09; H, 1.67; N, 11.58. Found: C, 33.29; H, 1.41; N, 11.66. 
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7-Bromo-3-(4-fluoro-phenyl)-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine (25): 
 
N
N
N
N
H
NBr
F
25
 
To a stirred solution of 23 (0.65 g, 1.7 mmol) in MeOH (9 mL), H2NNH2·H2O (0.361 g, 6.4 mmol, 
3.6 equiv) was added at rt. The reaction mixture was refluxed for 6 h, then was cooled to rt. The 
precipitated white solid was collected by filtration, washed with MeOH to remove side products and 
unreacted starting material, then dried to obtain 25 as a white shiny solid (0.354 g, 67 %). 
m.p. = 297-300 oC, Rf = 0.46 
 
1HMR (300 MHz, DMSO-d6) = 11.68 (brs, 1H), 7.84-7.74 (m, 2H), 735-7.25 (m, 2H), 5.24 (s, 
2H). 
 
13C NMR (75MHZ, DMSO-d6) = 162.9, 147.3, 138.0, 137.0, 130.6, 127.3 (x 2), 115.6 (x 2), 44.9. 
 
Anal Calcd for C10H7BrFN5: C. 40.56, H. 2.38, N. 23.65. Found: C. 40.20, H. 2.60, N. 23.45. 
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7-(4-Isopropoxyphenyl)-3-phenyl-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine (17) 
 
N
N
N
N
H
NO
17
 
 
To a stirred solution of the bromide 10 (0.05 g, 0.18 mmol) in DMF (1 mL), 4-
isopropoxyphenylboronic acid, (0.032 g, 1.0 equiv) and K3PO4 (0.114 g, 3 equiv) were added under 
nitrogen, followed by H2O (0.5 mL). The reaction mixture was degassed with nitrogen for 15 min, 
then PdCl2(PPh3)2 (0.006, 0.05 equiv) was added and the mixture was again degassed with nitrogen 
for 15 min. The reaction mixture was heated to 140 °C for 2 h, then was cooled to rt. and H2O (5 
mL) was added. The aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated. The residue was purified by flash column 
chromatography (hexane- EtOAc 65:35) to afford 17 (0.035 g 60 %). 
 
m.p. = 258-261 °C, Rf = 0.3 (hexane- EtOAc 1:1). 
 
1H NMR (300 MHz, DMSO-d6) = 11.52 (s, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.80-7.70 (m, 2H), 7.48-
7.37 (m, 3H), 6.96 (d, J = 8.8 Hz, 2H), 5.31 (s, 2H), 4.65 (ept, J 6.2 Hz, 1H), 1.26 (d, J = 6.2 Hz, 
6H). 
 
Anal Calcd for C19H19N5O: C. 68.45; H. 5.74; N. 21.01. Found: C. 68.71; H. 5.55; N. 21.30. 
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3-Phenyl-7-pyridin-3-yl-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine (6f) 
 
N
N
N
N
H
N
N
18
 
To a stirred solution of the bromide 10 (0.2 g, 7.1 mmol) in DMF (2.5 mL), 3-pyridineboronic acid, 
(0.088 g, 1.0 equiv) and K3PO4 (0.459 g, 3 equiv) were added under nitrogen, followed by H2O (1.5 
mL). The reaction mixture was degassed with nitrogen for 15 min, then PdCl2(PPh3)2 (0.025g, 0.05 
equiv) was added and the mixture was again degassed with nitrogen for 15 min. The reaction 
mixture was heated to 140 °C for 2 h, then was cooled to rt. and H2O (20 mL) was added. The 
aqueous phase was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated. The residue was purified by flash column chromatography (40 
% EtOAc in hexane) to afford 18 (0.140 g, 70 %) 
 
m.p. = 295-299°C, Rf = 0.2 (hexane- EtOAc 1:1). 
 
1HMR (300 MHz, DMSO-d6) = 11.70 (brs, 1H), 9.18-9.08 (m,1H), 8.67-8.57 (m, 1H), 8.31-8.22 
(m, 1H), 7.85-7.71 (m, 2H), 7.58-7.39 (m, 4H), 5.39 (s, 2H). 
. 
13C NMR (75MHZ, DMSO-d6) = 150.1, 147.3, 146.7, 137.3, 134.3, 132.9, 129.5, 128.6 (x 2), 
126.8, 125.0 (x 2), 124.0, 45.3. 
 
Anal Calcd for C15H12N6C. 65.21, H. 4.38, N. 30.42. Found: C. 65.49, H. 4.11, N. 30.13. 
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3-Phenyl-7-(4-trifluoromethylphenyl)-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazine (19) 
 
N
N
N
N
H
NF3C
19
 
 
To a stirred solution of the bromide 10 (0.1 g, 0.36 mmol) in DMF (2 mL), 4-
trifluoromehtylphenylboronic acid, (0.068 g, 1.0 equiv) and K3PO4 (0.228 g, 3 equiv) were added 
under nitrogen, followed by H2O (1 mL). The reaction mixture was degassed with nitrogen for 15 
min, then PdCl2(PPh3)2 (0.012 g, 0.05 equiv) was added and the mixture was again degassed with 
nitrogen for 15 min. The reaction mixture was heated to 140 °C for 2 h, then was cooled to rt. and 
H2O (20 mL) was added. The aqueous phase was extracted with EtOAc (3 × 15 mL). The combined 
organic layers were dried (Na2SO4), filtered and concentrated. The residue was purified by flash 
column chromatography (hexane- EtOAc 7:3) to afford 19 (0.075 g, 61 %) 
m.p. = 285-288 °C, Rf = 0.78 (hexane- EtOAc 1:1). 
 
1H NMR (300 MHz, DMSO-d6) = 11.64 (s, 1H), 8.15 (d, J = 8.1 Hz, 2H), 7.81 (d, J = 8.1 Hz , 2H), 
7.79-7.73 (m, 2H), 7.48-7.40 (m, 3H), 5.37 (s, 2H). 
 
13C NMR (75MHz, DMSO-d6) = 157.9, 147.8, 137.6, 135.2, 134.7, 129.8, 128.9, 126.8, 126.4, 
125.4, 45.7. 
Anal Calcd for C17H12F3N5: C. 59.48; H. 3.52; N. 20.40. Found: C. 59.75; H. 3.82; N. 20.11. 
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3-(3-Phenyl-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-7-yl)-phenol (20) 
 
 
N
N
N
N
H
N
HO
20
 
 
To a stirred solution of the bromide 10 (0.1 g, 0.36 mmol) in DMF (2 mL), 3-hydroxypheylboronic 
acid, (0.049 g, 1.0 equiv) and K3PO4 (0.228 g, 3 equiv) were added under nitrogen, followed by 
H2O (1 mL). The reaction mixture was degassed with nitrogen for 15 min, then PdCl2(PPh3)2 (0.012 
g, 0.05 equiv) was added and the mixture was again degassed with nitrogen for 15 min. The 
reaction mixture was heated to 140 °C for 2 h, then was cooled to rt. and H2O (20 mL) was added. 
The aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated. The residue was purified by flash column chromatography 
(hexane- EtOAc 6:4) to afford 20 (0.075 g, 61 %).  
Rf = 0.47(hexane- EtOAc 1:1). 
 
1H NMR (300 MHz, DMSO-d6) = 11.54 (s, 1H), 9.55 (s, 1H), 7.80-7.67 (m, 2H), 7.50-7.34 (m, 
5H), 7.22 (dd, J = 8.07, 8.07 Hz 1H), 6.78 (dd, J = 8.07, 2.2 Hz, 1H), 5.33 (s, 2H). 
 
Anal Calcd for C16H13N5O: C. 65.97; H. 4.50; N. 24.04. Found: C. 66.11; H. 4.21; N. 24.34. 
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1-[3-(3-Phenyl-1,4-dihydro-[1,2,4]triazolo[5,1-c][1,2,4]triazin-7-yl)-phenyl]-ethanone (21) 
 
N
N
N
N
H
N
O
21
 
To a stirred solution of the bromide 10 (0.1 g, 0.36 mmol) in DMF (2 mL), 3-acetylpheylboronic 
acid, (0.058 g, 1.0 equiv) and K3PO4 (0.228 g, 3 equiv) were added under nitrogen, followed by 
H2O (1 mL). The reaction mixture was degassed with nitrogen for 15 min, then PdCl2(PPh3)2 (0.012 
g, 0.05 equiv) was added and the mixture was again degassed with nitrogen for 15 min. The 
reaction mixture was heated to 140 °C for 2 h, then was cooled to rt. and H2O (20 mL) was added. 
The aqueous phase was extracted with EtOAc (3 × 15 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated. The residue was purified by flash column chromatography 
(hexane- EtOAc 6:4). To afford 21 (0.079 g, 70 %) 
m.p. = 264-267 °C, Rf = 0.64 (hexane- EtOAc 1:1). 
 
1H NMR (300 MHz, DMSO-d6) = 11.62 (s, 1H), 8.45 (s, 1H), 8.19 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 
8.2 Hz, 1H), 7.81-7.70 (m, 2H), 7.62 (dd, J = 8.2, 8.2 Hz, 1H), 7.51- 7.40 (m, 3H), 5.37 (s, 2H), 
2.62 (s, 3H). 
 
13C NMR (75MHz, DMSO-d6) = 197.6, 158.0, 147.3, 137.2, 134.3, 131.4, 129.9, 129.5, 129.3, 
128.9, 128.6 (x 2), 125.0 (x 2), 45.2, 26.8. 
Anal Calcd for C18H15N5O: C. 68.13; H. 4.76; N. 22.07. Found: C. 68.42; H. 
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